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Η επίδραση της διατροφής με νιτρικά στην βαρύτητα της νόσου, την ενδοθηλιακή λειτουργία, 
και δείκτες οξειδωτικού στρες ασθενών με χρόνιες παθήσεις. 
 
Περίληψη 
Οι ασθενείς με χρόνιες νόσους όπως η χρόνια αποφρακτική πνευμονοπάθεια (ΧΑΠ) και η 
ρευματοειδής αρθρίτιδα (ΡA) συχνά εμφανίζουν ενδοθηλιακή δυσλειτουργία και αγγειακά 
προβλήματα, τα οποία συσχετίζονται με την εμφάνιση καρδιαγγειακής νόσου. Υπάρχουν πολλοί 
παράγοντες που επηρεάζουν τη λειτουργία του ενδοθηλίου, ένας εκ των οποίων είναι η 
διατροφή. Υπάρχουν προτάσεις ότι η κατανάλωση χυμού παντζαριού (ΧΠ) μπορεί να 
μεταβάλλει την ενδοθηλιακή λειτουργία σε υγιή άτομα. Ωστόσο, υπάρχουν λιγοστές αναφορές 
σχετικά με την επίδραση του ΧΠ στην ενδοθηλιακή λειτουργία ασθενών με χρόνιες παθήσεις. Ο 
σκοπός της παρούσας μελέτης ήταν να διερευνηθούν οι επιδράσεις της κατανάλωσης ΧΠ για 2 
εβδομάδες στη σοβαρότητα της νόσου, την ενδοθηλιακή λειτουργία και βιοχημικούς δείκτες σε 
ασθενείς με ΧΑΠ και ΡΑ. Δεκαοκτώ ασθενείς, 9 με ΧΑΠ (ηλικία: 60,9 ± 12,6; BMI: 26.0 ± 2.1) 
και 9 με ρευματοειδή αρθρίτιδα (ηλικία: 54,3 ± 11,7; ΒΜΙ: 26,9 ± 3,6), και 8 υγιείς μη καπνιστές 
μάρτυρες (ηλικία: 55,7 ± 6,8; ΒΜΙ: 27,8 ± 3,2; Ομάδα ελέγχου - ΟΕ) συμμετείχαν στη μελέτη. 
Οι συμμετέχοντες έλαβαν μέρος σε μια απλή τυφλή μελέτη και τυχαιοποιήθηκαν είτε στην 
πειραματική κατάσταση (κατανάλωση 70 ml χυμού παντζαριού ημερησίως για δύο εβδομάδες; 
χυμός παντζάρι - ΧΠ) ή στην κατάσταση ελέγχου (χυμός φραγκοστάφυλο; χυμός ελέγχου - ΧΕ). 
Υπήρχε μια περίοδος έκπλυσης δύο εβδομάδων μεταξύ των συνθηκών. Όλες οι μετρήσεις έγιναν 
νωρίς το πρωί, μετά από ολονύκτια νηστεία. Η ενδοθηλιακή λειτουργία βελτιώθηκε σημαντικά 
μετά την κατανάλωση ΧΠ τόσο στους ασθενείς με ΧΑΠ όσο και με ΡΑ, ενώ παρέμεινε σχετικά 
ανεπηρέαστη από την κατανάλωση του ΧΕ. Ο αιματοκρίτης μειώθηκε σημαντικά στους 
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ασθενείς με ΡΑ μετά την κατανάλωση του ΧΠ (39,2 ± 2,1 Vs 37,8 ± 1,8). Τα μονοκύτταρα 
μειώθηκαν σημαντικά στην ΟΕ μετά την κατανάλωση ΧΠ (0,52 ± 0,08 Vs 0,37 ± 0,05). Δεν 
παρατηρήθηκαν άλλες σημαντικές αλλαγές σε άλλες βιοχημικές και φυσιολογικές παραμέτρους 
σε οποιαδήποτε ομάδα μετά από την κατανάλωση ΧΠ ή ΧΕ. Η κατανάλωση ΧΠ για δύο 
εβδομάδες φαίνεται να είναι σε θέση να βελτιώσει τη λειτουργία του ενδοθηλίου σε ασθενείς με 
ΡΑ και ΧΑΠ. Ωστόσο, η μακροχρόνια κατανάλωση BJ θα μπορούσε επίσης να οδηγήσει σε 
αλλαγές σε φυσιολογικούς και βιοχημικούς δείκτες που δεν παρατηρήθηκαν μετά από δύο 
εβδομάδες παρέμβασης. 
 
Λέξεις κλειδιά: διαιτητικά νιτρικά, ενδοθηλιακή λειτουργία, οξειδωτικό στρες, ρευματοειδής 
αρθρίτιδα,  χρόνια αποφρακτική πνευμονοπάθεια 
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The effect of dietary nitrates in the severity of disease, the endothelial function and indices of 
oxidative stress in patients with chronic diseases. 
 
Abstract 
Patients with chronic diseases like obstructive pulmonary disease (COPD) and rheumatoid 
arthritis (RA) often present endothelial dysfunction and vascular problems, which correlate with 
the occurrence of cardiovascular disease (CVD). There are several factors that affect the 
endothelial function, one of which is nutrition. There are suggestions that beetroot juice (BJ) 
consumption might alter the endothelial function in healthy individuals. However, there are 
scarce reports on the effect of BJ on the endothelial function of patients with chronic diseases. 
The purpose of the present study was to investigate the effects of BJ consumption for 2 weeks on 
the severity of disease, endothelial function and biochemical indices in COPD and RA patients. 
Eighteen patients, 9 with COPD (age: 60.9 ± 12.6; BMI: 26.0 ± 2.1) and 9 with RA (age: 54.3 ± 
11.7; BMI: 26.9 ± 3.6), and 8 healthy non-smoking controls (age: 55.7 ± 6.8; BMI: 27.8 ± 3.2; 
control group - CG) participated in the study. Participants took part in a single blinded study and 
they were randomly assigned to either the experimental (70 ml of beetroot juice consumption 
daily for two weeks; beetroot juice - BJ) or the control condition (blackcurrant juice; control 
juice - CJ). There was a two-week washout period between conditions. All measurements were 
done early in the morning, following an overnight fast. Endothelial function significantly 
improved following BJ consumption in both COPD and RA patients, whereas it remained 
relatively unaffected by the consumption of the CJ. Hematocrit significantly decreased in RA 
patients following BJ consumption (39.2 ± 2.1 Vs 37.8 ± 1.8). Monocytes significantly decreased 
in the CG following BJ consumption (0.52 ± 0.08 Vs 0.37 ± 0.05) No other significant changes 
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in other biochemical and physiological parameters were observed in any group following BJ or 
CJ consumption. A two-week consumption of BJ seems to be able to improve endothelial 
function among patients with RA and COPD. However, long-term BJ consumption may also 
result in changes in physiological and biochemical indices that were not observed after two 
weeks of intervention. 
 
Key words: dietary nitrates, endothelial function, oxidative stress, rheumatoid arthritis, chronic 
obstructive pulmonary disease 
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1. INTRODUCTION 
 
Patients with diseases like chronic obstructive pulmonary disease (COPD) and Rheumatoid 
arthritis (RA) often present endothelial dysfunction and vascular problems, which correlate with 
the occurrence of cardiovascular disease that is often present in these diseases, and the 
pathophysiology of each disease (Kelm & Schrader, 1990; Davignon and Ganz, 2004; Sattar et 
al., 2003; Moro et al 2008). Patients with COPD and RA are usually taking many medicines. 
Therefore, the purpose of the present study was to investigate the effects of beetroot juice (BJ) 
consumption for 2 weeks on the severity of disease, endothelial function and biochemical indices 
in RA and COPD patients. 
RA is a chronic autoimmune multisystemic inflammatory disease which affects many organs but 
predominantly attacks the synovial tissues and joints. Onset is peaking in the 4th and 5th 
decades. RA has an overall prevalence of 0.5-1%, with a female predominance, with the disease 
being 2-3 times more common in women (Gabriel, 2001). Alternative therapies have been used 
in RA with promising results, such as mediterranean diet which can improve certain health 
indicators such as blood pressure, glucose metabolism, lipid profile, as well as reduce 
inflammation and markers of oxidative stress (González Cernadas et al., 2014), and others such 
as fish oil, olive oil, probiotics and physical activity. 
COPD is characterized by persistent respiratory symptoms and airflow limitation due to airway 
and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases 
(Global Initiative for Chronic Obstructive Lung Disease, 2017). Major risk factor is cigarette 
smoking; other risk factor is occupational exposure to dust, chemicals and indoor air pollution 
from biomass fuel burning. COPD is a common disease, with a highest prevalence among those 
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over 60 years old, with an estimated prevalence worldwide of 10% (Halbert et al., 2006). 
Alternative therapies include fruits and vegetables, omega-3 fatty acids and dietary antioxidants 
(i.e. vitamin C). 
Nitric oxide (NO) is a colorless gas that is not readily soluble in water, while it is highly reactive 
with other elements. NO is an important component in many physiological processes, but mostly 
in the function of smooth muscle surrounding arteries; muscle expansion and contraction 
(Vincent, 2010; Brown, 1999; Reid, 2001). The major product of NO after oxidation in aqueous 
solutions is nitrate (Kelm, 1999). The nitrate-nitrite-NO pathway plays an important 
physiological and therapeutic role in the human body (Lundberg, 2009). Dietary nitrate (i.e. 
inorganic nitrate anion NO3-) is found in large amounts in vegetables such as beetroot. NO may 
have anti-inflammatory, antiadhesive and vasodilating properties. In chronic diseases, systemic 
inflammation causes a significant reduction in NO bioavailability by affecting substantially the 
extensibility of the arteries and eventually causing severe vascular problems. Foods with high 
concentrations of dietary nitrates increase NO in serum. Dietary nitrates have a wide range of 
beneficial effects such as: blood pressure reduction, improvement of endothelial dysfunction, 
enhancement of performance during exercise. Both healthy people and patients with peripheral 
vascular disease that consume a diet rich in nitrates may have protection against ischemia, and 
also reduce arterial stiffness (Lidder & Webb, 2013). 
Recent studies have shown that modern pharmacology has significantly improved the treatment 
of Rheumatoid Arthritis (RA). An increasing number of RA patients are using various 
complementary and alternative medicine (CAM) approaches for relief of symptoms and general 
well-being. CAM is the term for medical products and practices that are not part of standard care 
and are not generally taught in conventional medical universities. Alternative medicine is used 
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instead of modern pharmacology, whereas complementary medicine is used in the same time 
with it. CAM has been mainly used to treat back pain or other back problems, neck pain, joint 
pain or stiffness and anxiety or depression in RA patients (Barnes Pat al., 2002). 
Αlternative forms of treatment to relieve symptoms have been used also, which have been 
identified in part by the American College of Rheumatology (ACR), with extensive reviews 
which include alimentation and types of exercise and meditation. These alternative therapeutic 
approaches are intended to relieve back and neck pain and also to relieve anxiety and depression 
and for this reason the physician rheumatologist should be aware of any alternative use, 
preparations or treatments. 
Diet and nutrition may also be important modifiable risk factors for the development, 
progression and management of obstructive lung diseases such as asthma and chronic obstructive 
pulmonary disease (COPD). Important roles for many nutrients have been suggested of which 
some are supported by epidemiological studies, in vivo and after animal testing. Although, very 
few human intervention trials are available to definitively assess the efficacy of different 
approaches to nutritional management of respiratory diseases diet, nutrition and exersise are 
increasingly becoming recognized as modifiable contributors to chronic disease development and 
progression. Today evidence has emerged indicating the importance of dietary intake in 
obstructive lung diseases such as asthma and chronic COPD in both early life and disease 
development (Nurmatov et al., 2011; Varraso et al., 2007) and management of disease 
progression (Shaheen et al., 2010, 36, 277–284; Scott et al., 2014). 
Pharmacological management remains the mainstay for treatment of respiratory diseases. While 
treatment options are advancing, dietary intake modification could be an important adjuvant to 
disease management. 
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Pulmonary rehabilitation should be considered part of integrated patient management, and 
usually includes a cooperation of a wide range of healthcare professionals and a long period of 
time, to ensure optimum coverage of the many aspects involved (Vogiatzis et al., 2016). 
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2. LITERATURE REVIEW 
 
 
2.1. RHEUMATOID ARTHRITIS 
 
Rheumatoid arthritis (RA) is a chronic autoimmune multisystemic inflammatory disease which 
affects many organs but predominantly attacks the synovial tissues and joints. 
 
2.1.1. AETIOLOGY-PATHOPHYSIOLOGY 
 
Clinical presentation. Onset may be insidious or abrupt. Early features commonly include 
tiredness, malaise and generalised aches. Arthritis symptoms usually first develop in the hands 
and wrists in a characteristic symmetric, proximal distribution. Feet and large joints may also be 
involved in a later stage. 
 
Pathology. Aetiology is unknown, and probably multifactorial. It is considered that a genetic 
predisposition (HLA-DR B1 which is the most common allele of HLA-DR4 involved in 
RA) combined with an environmental trigger (EBV postulated as a possible antigen, but not 
proven) may  lead to an autoimmune response that is directed against synovial structures and 
other organs. 
The process of activation and accumulation of T CD4 cells in the synovium starts a cascade of 
inflammatory responses:  
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- Initially the activation of the macrophages and synovial cells that leads to the production of 
cytokines such as IL4 and TNF, which in turn cause proliferation of the synovial cells and 
increase production of destructive enzymes such as elastase and collagenase by macrophages. 
- Secondly the activation of B cell lymphocytes to produce various antibodies including 
rheumatoid factor (RF-IgM antibodies against Fc portion of the IgG) which results in immune 
complexes that deposit in different tissues and contribute to further injury.  
- By directly activating endothelial cells via increased production of VCAM1, there is an 
increase in the adhesion and further accumulation of inflammatory cells. 
- Finally, by producing RANKL, which in turn activates osteoclasts causing subchondral bone 
destruction. 
The inflammatory response leads to pannus formation, which is an oedematous thickened 
hyperplastic synovium infiltrated by lymphocytes T and B, plasmocytes, macrophages and 
osteoclasts. Pannus gradually erodes bare areas initially, continued by the articular cartilage. It 
causes a fibrous ankylosis which gradually ossifies (Sommer et al., 2005). 
 
Diagnostic criteria. Diagnosis is based on a combination of clinical, radiographic and serological 
criteria. The 2010 ACR - EULAR classification criteria for Rheumatoid Arthritis 4 requires a 
score of >6/10 for a diagnosis of RA to be made: 
          A- Joint Involvement 
0: Large Joint 
1: 2-10 large joints 
2: 1-3 small joints (with or without involvement of large joints) 
3: 4-10 small joints (with or without involvement of large joints) 
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5: >10 joints (at least 1 small joint) 
        B- Serology 
0: Negative RF and negative ACPA 
2: Low-positive RF or low-positive ACPA 
3: High-positive RF or high-positive ACPA 
       C- Acute Phase Reactants 
0: Normal CRP and Normal ESR 
1: Abnormal CRP and Abnormal ESR 
        D- Duration of Symptoms 
0: <6 weeks 
1: >6 weeks 
 
Non-musculoskeletal features of RA tend to occur late in the disease and include: 
   Α. pulmonary involvement, 
   Β. cardiovascular disease that leads to an accelerated coronary artery and cerebrovascular 
atherosclerosis (Turesson et al., 1999), pericarditis and vasculitis (occurs mainly with a severe 
erosive disease, rheumatoid nodules and high RF titres), 
   C. cutaneous involvement consists in rheumatoid nodules formation, which is usually seen in 
pressure areas: elbows, occiput, lumbosacral (Robbins et al., 2010) and occurs in RF-positive 
patients (Ziff, 1990), 
   D. ocular involvement: keratoconjunctivitis sicca, uveitis, episcleritis. 
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Markers 
There are various serological markers for rheumatoid arthritis: 
1. The rheumatoid factor (RF) which is an IgM antibody against FC portion of the IgG 
antibodies, and is a traditional marker but is nonspecific that is associated with several 
autoimmune and chronic infectious diseases. 
2. The anti-cyclic citrullinated peptide (anti-CCP) which is more than 80% sensitive and 
more than 95% specific. 
3. Elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). 
 
2.1.2. EPIDEMIOLOGY 
RA has an overall prevalence of 0.5-1%, with a female predominance, with the disease being 2-3 
times more common in women (Gabriel, 2001). Onset is peaking in the 4th and 5th decades. 
 
 
2.1.3. METHODS OF TREATMENT 
 
2.1.3.1. MEDICATIONS 
 
Abatacept (Orencia). Abatacept is used for treatment of moderate to severe RA in adults and 
juvenile rheumatoid arthritis. Oftenlly prescribed after failure of a DMARD, like methotrexate 
but it can also be used as a first-line therapy for inflammatory joint conditions causing joint pain, 
swelling, redness and morning stiffness. The drug decreases the interactions of T cells and B 
cells to lessen joint inflammation. 
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Anakinra (Kineret). Anakinra (Kineret) is used to treat RA neonatal-onset multisystem 
inflammatory disease (NOMID), and other autoimmune diseases. It is a “biologic” medicine, 
which means that it is man-made through genetic-engineering techniques and closely related to a 
protein that occurs naturally in the body, and is used for the decrease of inflammation in arthritis. 
 
Apremilast (Otezla). Apremilast (Otezla) is a small molecule prescription medicine that is used 
to psoriatic arthritis treatment and moderate to severe plaque psoriasis patients that are 
candidates for phototherapy (treatment of the skin with an ultraviolet light source). Apremilast 
slows the production of an enzyme called phosphodiesterase 4 (PDE4) and results to a reduction 
of inflammation. 
 
Azathioprine (Imuran). Azathioprine (Imuran) is a drug used to treat dermatomyositis, systemic 
lupus erythematosus (lupus), inflammatory bowel disease and vasculitis (inflammation of the 
blood vessels), by suppressing the immune system. Azathioprine can also be used to treat RA, 
but it is not used as commonly as other DMARDs like methotrexate, though being an 
immunosuppressant also. Immunosuppressants may decrease joint damage and disability. 
 
Cyclophosphamide (Cytoxan).Cyclophosphamide is reserved for severe, refractory rheumatoid 
arthritis or severe complications of lupus, myositis, scleroderma, or vasculitis. It belongs to a 
class of drugs known as alkylating agents, and have been used against cancer, been considered a 
potent immunosuppressant. Cyclophosphamide blocks the production of the deoxyribonucleic 
acid (DNA) in cells, by preventing cells from dividing, causing cell death. Such cells affected are 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:03:26 EEST - 137.108.70.13
Σ ε λ ί δ α  | 25 
 
25 
 
immune cells. They are used in autoimmune diseases such as RA, lupus, scleroderma or 
vasculitis. 
 
Cyclosporine (Neoral, Sandimmune, Gengraf).  Cyclosporine (Neoral, Sandimmune, Gengraf) is 
a potent immunosuppressant drug that is considered a DMARD, because it not only decreases 
the pain and swelling of arthritis, but it also may prevent joint damage and by this way reduce 
the risk of long term disability. It is helpfull with pain and swelling and also slows the 
progression of arthritis by long use. Cyclosporine is sometimes used to treatment of RA and 
other autoimmune diseases. 
 
Hydroxychloroquine (Plaquenil). Hydroxychloroquine (Plaquenil) is considered DMARD, 
because it decreases pain and swelling of arthritis, and may prevent joint damage and reduce the 
risk of long-term disability. 
 
Leflunomide (Arava). Leflunomide (Arava) is a drug used approved to treat moderate to severe 
rheumatoid arthritis in adultsand is a DMARD. This class of medicines can decrease joint 
damage and disability caused by rheumatoid arthritis. Leflunomide blocks the formation of 
DNA, and therefore suppresses the immune system resulting to reduced inflammation. However, 
it is not completely clear how this medication works in rheumatoid arthritis. 
 
Methotrexate (Rheumatrex, Trexall). Methotrexate (Rheumatrex, Trexall, Otrexup, Rasuvo) is 
one of the most effective and commonly used immunosuppressant in the treatment of several 
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forms of rheumatic conditions. It is a DMARD, it decreases pain and swelling of arthritis, and 
also can decrease damage to joints and long-term disability. 
 
Minocycline (Minocin). Minocycline (Minocin) is a tetracycline (antibiotic) and also belongs to 
DMARDs. Although RA is not thought to be caused by an infection, minocycline has shown to 
improve the signs and symptoms of this disease.  
 
Mycophenolate Mofetil & Mycophenolate Sodium. Mycophenolate Mofetil (CellCept) and 
Mycophenolate Sodium (Myfortic) are used in the treatment of several autoimmune diseases. 
Mycophenolate was used originally in the management of patients with organ transplants. 
 
Nonsteroidal anti-inflammatory drugs (NSAIDs). Traditional NSAIDs include Aspirin, ibuprofen 
(Advil, Motrin, etc.), naproxen (e.g., Aleve) and the newer Celecoxib (Celebrex) which belongs 
to a newer class of NSAIDs, the “COX-2 inhibitor” or a “COX-2 selective” NSAID,  are some of 
the most commonly used pain medicines in adults and can decrease inflammation, such as in 
arthritis. NSAIDs can be very effective medications rheumatic diseases. 
 
Rituximab (Rituxan & MabThera). Rituximab (Rituxan and MabThera) is a drug used to treat 
RA that has not responded to other types of medications, and also to certain forms of vasculitis. 
It works by turning off a part of the immune system that mulfunctions in autoimmune diseases. 
 
Sulfasalazine (Azulfidine). Sulfasalazine (Azulfidine) belongs to a class of drugs called sulfa 
drugs against pain and swelling in arthritis. Resulting form  a combination of salicylate (the main 
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ingredient in aspirin) and a sulfa antibiotic is known as a DMARD, because it not only decreases 
the pain and swelling of arthritis, but also prevents damage to joints and long-term disability. 
 
TNF Inhibitors. TNF inhibitors reduce inflammation and stop disease progression and are used in 
inflammatory conditions such as RA, psoriatic arthritis, juvenile arthritis, inflammatory bowel 
disease (Crohn’s and ulcerative colitis), ankylosing spondylitis and psoriasis.  
 
Tocilizumab (Actemra).Tocilizumab is administered as a monthly intravenous infusion or a 
subcutaneous injection every 1-2 weeks. It is a biologic drug approved for treatment of adults 
RA, in polyarticular juvenile rheumatoid arthritis (PJIA) as well as at the systemic form of 
juvenile idiopathic arthritis (SJIA) in children. Biologic drugs are used to suppress the immune 
system.Tocilizumab is used to stop inflammation, by blocking the interleukin (IL)-6 receptor. 
The medicine is injected once every 1-2 weeks or infused through an IV each month. 
 
Tofacitinib Citrate (Xeljanz).  Tofacitinib citrate (Xeljanz®) is an oral drug used to treat adults 
with moderate-to-severe, active rheumatoid arthritis who haven’t responded to methotrexate.  
Tofacitinib acts to block the body’s production of enzymes called Janus kinases (JAKs) which 
have a role in joint inflammation in RA. If left untreated, RA inflammation could lead to joint 
erosions and organ and tissue damage. It may be used alone or in combination with methotrexate 
or other DMARDs. Tofacitinib is currently studied for use in other autoimmune diseases, 
including psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease and ankylosing 
spondylitis (American College of Rheumatology, 2017). 
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Treatment and prognosis. 
Current treatment of RA consists in improving the symptoms and slowing disease progression. 
Therapy conbines corticosteroids, NSAIDs, DMARDs and TNF antagonists.  
RA carries a significant burden of disability and a reduction in life expectancy. Excess mortality 
is usually related to its non-articular manifestations (Chehata et al., 2001; Young et al., 2007). 
 
 
2.1.3.2. DIET - OTHER THERAPEUTIC APPROACHES 
 
Diet 
It has been shown that the Mediterranean diet can improve certain health indicators such as 
blood pressure, glucose metabolism, lipid profile, as well as reduce inflammation and markers of 
oxidative stress (González Cernadas et al., 2014). 
 
Food supplements 
Fish oil. Fish oil is rich in omega-3 polyunsaturated fatty acids (PUFAs), which are associated 
with a reduction in inflammatory markers such as TNF-a and interleukin-1 (Calder, 2008; 
Proudman et al., 2008). These characteristics are similar to anti-inflammatory and anti-TNF 
blockers used in the treatment of RA. 
Fish oil is recommended by the American Heart Association for reducing events in patients with 
coronary heart disease (CHD), and therefore the RA patients can take advantage of the additional 
fish oil intake, by both preventing elevated rates of CHD and reducing inflammation (Kris- 
Etherton et al., 2002). 
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Indeed, a meta-analysis has shown that cosuming fish oil in an amount greater than 2.7 gr/day for 
more than 3 months may result in reducing the amount of non-steroidal antiinflammatory drugs 
(NSAIDs) required (Lee et al., 2012). 
Interestingly, a systematic review that studied the effect of omega-3 fatty acids in patients with 
PA, demonstrated a moderate beneficial effect on joint swelling, pain, duration of morning 
stiffness, the generalized estimation of pain and disease activity, and lower doses of NSAIDs 
(Miles & Calder, 2012). 
 
Olive oil. Virgin olive oil contains several substances with excellent anti-inflammatory and 
antioxidant effects (Lucas et al., 2011). The main components are oleic acid, linolenic acid, alpha 
linolenic acid, and phenolic compounds (Waterman & Lockwood, 2007; Wardhana et al., 2011). 
A study on supplementation with olive oil in patients with RA who were already taking fish oil, 
observed that the combination of both oils resulted in more early and intense clinical and 
laboratory improvement of participants (Berbert et al., 2005). 
 
Vitamin D. Vitamin D is involved in bone metabolism, and its deficiency is associated with 
osteopenia, a disorder that often coexists in the PA. Furthermore, the effects of vitamin D are 
extending to the regulation of immune system and interfere with both the innate and the acquired 
immune systems (Wen & Baker, 2011). 
In vitro studies demonstrate the inhibition of activation of interleukins IL-2, IL-12 and IL-6, and 
interferon-gamma (IF-c) and TNF. Instead, vitamin D promotes the differentiation of monocytes 
into macrophages, and further displays anti-inflammatory characteristics, through the ability of 
prostaglandins output adjustment (Kriegel et al., 2011). 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:03:26 EEST - 137.108.70.13
Σ ε λ ί δ α  | 30 
 
30 
 
Generally multi research analysis suggests that vitamin D deficiency is associated with increased 
risk of developing RA, while vitamin D supplements could have a role in the treatment of RA 
(Song et al., 2012). Also, a team of researchers has demonstrated improved disease course after 
increased intakes of calciferol for a year (Brohult & Jonson, 1973). 
In another study, it appeared that the administration of vitamin D, as additional of treatment with 
DMARDs, is associated with decreased pain. It is important that no side effects were observed 
during administration of vitamin D (Andjelkovic et al., 1999). 
 
Probiotics. Probiotics are live microorganisms which when administered in adequate amounts 
are beneficial for host’s health (FAO / WHO, 2006). The current understanding is that probiotics 
can be used in the treatment of chronic diseases such as flegmonondon PA (Yeoh et al., 2013). 
It has been shown that the Lactobacillus casei induces improvement of histopathological changes 
and intra-articular lymphocytic infiltrates, likewise those of the administration of methotrexate 
(MTX) (So et al., 2008). 
Today there are signs that probiotics has beneficial effects on pain sensitivity and articular 
edema, and have also shown a decrease in various inflammation markers (Alipour et al., 2014). 
Most importantly, no side effects were observed during administration of probiotics. 
 
Herbal Medicine. Some herbs have interaction with mediators of inflammation and therefore 
may be used in the treatment of rheumatoid arthritis (Yang et al., 2013; Cameron et al., 2009). 
They can act as antagonists of free radicals, but in other ways, such as capsaicin, which acts 
competitively high of TRPV1 receptors resulting in the local call of substance P, which is 
believed to interfere with the pain relieving device (Cameron et al., 2011). 
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Extract of the herb Tripterygium Wilfordii (TWE; Vine of the god of thunder) was used in 
eleven randomized controlled trials of 940 people with unsafe results (Liu et al., 2013). The 
TWE is incorporated in Chinese medicine with major components of triptolide (triptolide) and 
celastrol (quinone triterpene). Triptolide exhibits anti-inflammatory, antiproliferative and 
proapoptotic effects and diversifies the immune system (Liu, 2011). Moreover, TWE may show 
protective cartilage actions (Bao & Dai, 2011; Moudgil et al., 2011). 
 
Other therapeutic approaches 
 
Physical activity. Lack of physical activity is the 4th pre-disposing factor of mortality mortality 
(World Health Organization, 2009). Exercise leads to smaller percentages of vascular heart 
disease, hypertension, cerebral ischemic attacks, metabolic syndrome, bowel and breast cancer, 
depression, and death from all causes (US Department of Health and Human Services, 2008), 
while decreases the likelihood of fracture and bone density reduction, and increases muscle 
mass, strength and intrinsic neuromuscular activity (US Department of Health and Human 
Services, 2008; Tremblay et al., 2011). Although the PA has been shown that physical activity 
increases the stress on the joints, pain, disease activity and joint destruction, Hurkmans al. (2009) 
suggested the combination of aerobic exercise and resistance training in the daily practice of 
patients with RA. Therefore, exercise may be recommended in patients with RA, while any 
physical activity should have a low joint impact to avoid pain and musculoskeletal injury (US 
Department of Health and Human Services, 2008). 
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Yoga. In modern literature, it has been suggested that mind-body interventions, such as Yoga 
which combines the management of stress with physical activity, may be beneficial. Yoga 
regulates sweating during dynamic exercise and improves the strength of the respiratory muscles, 
the strength of the hand and the grip, and elasticity (Oken et al., 2004; Madanmohan Mahadevan 
et al., 2008; Hart & Tracy, 2008). Scientific studies have shown improvement of the 
questionnaire results DAS28 (Badsha et al., 2009; Haaz & Bartlett, 2011), and side effects have 
not been reported from the use of yoga (Uhlig, 2012). It has been demonstrated that it could also 
be used in younger patients with RA (Evans et al., 2013). 
 
Tai Chi. Tai Chi is a martial Chinese art which combines meditation with slow soft and graceful 
movements with deep breaths and relaxing (Wang, 2011) and could be used in older age patients 
with RA that have reduced strength, mobility and morbidities (increased cardiovascular risk, 
osteoporosis and depression) (Wang, 2011). No side effects have been reported from the use of 
Tai Chi (Wang, 2011). 
 
Meditation. Meditation incorporates multiple techniques in order to focus attention, empathy and 
inner peace. It can relieve psychosomatic and psychiatric disorders, and reduce cardiovascular 
risk (Grossman et al., 2004), pain (Kabat-Zinn et al., 1985), stress (Miller et al., 1995) and 
depression in patients with RA (Dickens et al., 2003; Ma & Teasdale, 2004) and fibromyalgia 
(Sephton et al., 2007). 
 
Acupuncture. Methods such as acupuncture (Ernst & Lee, 2010), the electroacupuncture (David 
et al., 1999) and acupuncture with bee venom (Lee et al., 2014) have been used in studies 
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without sufficient data for reliable conclusions. However, there are positive signs in reducing 
pain. 
Homeopathy. There are very limited clinical trials (Chatfield et al., 2011; Vithoulkas, 2011), 
while no contraindications have been reported. 
 
Hydrotherapy. Balneotherapy. Prolonged use of heat, pressure exerted by the water that transfers 
the vibrations from the skin deeper into the body cause mechanical irritation of the immune 
system, reduction of pain and inhibition of the sympathetic system (Gabrielsen et al., 2000). 
Most studies show positive results, but with low methodological quality (Kamioka et al., 2010). 
 
Joint Injection/Aspiration. Joint injections or aspirations (taking fluid out of a joint) are 
performed in an office or hospital setting, often with a cold spray or other local anesthesia. After 
the skin surface is thoroughly cleaned, the joint is entered with a needle attached to a syringe. At 
this point, either joint fluid can be obtained (aspirated) and used for appropriate laboratory 
testing or medications can be injected into the joint space. This technique also applies to 
injections into a bursa or tendon sheath to treat bursitis and tendonitis, respectively. Commonly 
injected joints include the knee, shoulder, ankle, elbow, wrist, base of the thumb and small joints 
of the hands and feet. Hip joint injection may require the aid of an ultrasound or X-ray called 
fluoroscopy for guidance. Some small joints may also be more easily aspirated or injected with 
aid of ultrasound (American College of Reumatology, 1027). 
 
Joint Surgery. Joint replacement surgery is typically recommended to patients who have tried 
non-surgical treatment but still have joint pain. While this is an extremely effective surgical 
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treatment, total joint replacement should be considered as the last, rather than the first, treatment 
option for patients with advanced arthritis of the hip, knee or shoulder. Modern joint replacement 
surgery involves removal of the worn cartilage from both sides of the joint, followed by 
resurfacing of the joint with a metal and plastic replacement implant that looks and functions 
much like your normal joint. Although nearly every joint in the body can be replaced, most 
replacement surgeries involve the hip or knee. Over the last 30 years, improved surgical 
techniques and new implant materials have been developed, making total joint replacement one 
of the most reliable and durable procedures in any area of medicine (American College of 
Reumatology, 1027). 
 
Clinical Research Trials. Participation in a clinical trial is entirely voluntary, and depends on an 
understanding of the possible benefits and risks associated with participating in a particular trial 
and happens after written approval of the participant. A variety of different medications have 
been used to treat patients who have arthritis and other rheumatic diseases. Before any of these 
medicines can be prescribed, the Federal Food and Drug Administration (FDA) has required 
strict testing for the safety and effectiveness. Testing and evaluation process is mainly done 
through clinical trials. Such trials, lasting from a few weeks to many years, determine how safe 
and effective new treatments are.  
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2.2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 
2.2.1. AETIOLOGY-PATHOPHYSIOLOGY       
Definition: Chronic obstructive pulmonary disease (COPD) is a common, preventable and 
treatable disease that is characterized by persistent respiratory symptoms and airflow limitation 
that is due to airway and/or alveolar abnormalities usually caused by significant exposure to 
noxious particles or gases (Global Initiative for Chronic Obstructive Lung Disease, 2017). 
 
Terminology. The current definition of COPD does not include the terms chronic bronchitis or 
emphysema. As chronic bronchitis we define the presence of productive cough for three months 
in each of two successive years in a patient in whom other causes of chronic cough 
(e.g. bronchiectasis) have been excluded. We don’t consider patients with chronic bronchitis as 
COPD, unless they have airflow obstruction. As emphysema we define the pathology of the 
destruction of the alveoli walls. This is one of the structural abnormalities that can be present in 
patients with COPD but can also be found in persons with normal lung function (Global 
Initiative for Chronic Obstructive Lung Disease, 2017). 
 
Etiology, pathobiology and pathology of COPD leading to airflow limitation and clinical 
manifestations. 
 
Pathology 
COPD is characterised by poorly reversible airflow obstruction and an abnormal inflammatory 
response in the lungs. The latter represents the innate and adaptive immune responses to long 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:03:26 EEST - 137.108.70.13
Σ ε λ ί δ α  | 36 
 
36 
 
term exposure to noxious particles and gases, particularly cigarette smoke. All cigarette smokers 
have some inflammation in their lungs, but not all of them develop COPD, patients having an 
enhanced or abnormal response to inhaling toxic agents. This amplified response may result in 
mucous hypersecretion (chronic bronchitis), tissue destruction (emphysema) and/or disruption of 
normal repair and defence mechanisms causing small airway inflammation and fibrosis 
(bronchiolitis). These pathological changes result in increased resistance to airflow in the small 
conducting airways, increased compliance of the lungs, air trapping and progressive airflow 
obstruction, resulting COPD. The cellular and molecular mechanisms underlying the 
pathological changes found in COPD, are largely understood. Pathology, pathogenesis, and 
pathophysiology William MacNee 
Chronic irritants cause an inflammatory response in the respiratory tract which is amplified in 
COPD-prone patients. Other environmental exposures such as bioamass fuel exposure and air 
pollution as well as genetic abnormalities, abnormal lung development and accelerated aging 
may contribute. Chronic inflammation leads to structural changes in the peripheral airways but 
also in the large airways, lung parenchyma and pulmonary vasculature (Hogg & Timens, 2009). 
The pattern of change varies between patients and can include narrowing or reduction in number 
of the small airways, destruction of the lung parenchyma or emphysema, enlarged mucous 
glands with mucus hypersecretion and hyperplasia of the wall of the small pulmonary arteries 
Global Initiative for Chronic Obstructive Lung Disease, 2017). 
 
Pathogenesis  
Inflammation is present in the lungs particularly the small airways of all people who smoke.This 
normal protective response to the inhaled toxins is amplified in COPD, leading to tissue 
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destruction and impairment of the defence mechanisms that limit such destruction and disruption 
of the repair mechanisms. These changes in the airways increase with disease severity and persist 
even after smoking cessation. Besides inflammation, there two other processes that are involved 
in the pathogenesis of COPD - an imbalance between proteases and antiproteases and an 
imbalance between oxidants and antioxidants (oxidative stress) in the lungs. Inflammatory cells 
that are present are neutrophils, macrophages and T lymphocytes (CD8 more than CD4) in the 
lungs. The extent of the inflammation is related to the degree of the airflow obstruction.These 
inflammatory cells release a variety of cytokines and mediators that participate in the disease 
process. This inflammatory pattern is markedly different from that of patients with asthma. 
Pathology, pathogenesis, and pathophysiology William MacNee 
 
Inflammatory mediators  
Many inflammatory mediators are increased in COPD, including Leucotriene B4, a neutrophil 
and T cell chemoattractant which is produced by macrophages, neutrophils and epithelial cells, 
chemotactic factors such as the CXC chemokines, interleukin 8 and growth related oncogene, 
which are produced by macrophages and epithelial cells. 
These attract cells from the circulation and amplifypro-inflammatory responses. Pro-
inflammatory cytokines such as tumour necrosis factor and interleukins 1 and 6, Growth factors 
such as transforming growth factor, which will facilitate fibrosis in the airways either directly or 
through release of another cytokine, connective tissue growth factor. Pathology, pathogenesis, 
and pathophysiology William MacNee 
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Protease and antiprotease imbalance  
Increased production of proteases and inactivation of antiproteases results in imbalance. 
Cigarette smoke and inflammation itself produce oxidative stress which primes several 
inflammatory cells to release a combination of proteases and inactivates several antiproteases by 
oxidation. The main proteases involved are those produced by neutrophils (including the serine 
proteases elastase, cathepsin G and protease 3) and macrophages (cysteine proteases and 
cathepsins E, A, L and S and various matrix metalloproteases (MMP-8, MMP-9 and MMP-12). 
The main antiproteases involved in the pathogenesis of emphysema are 1 antitrypsin, secretory 
leucoprotease inhibitor and tissue inhibitors of metalloproteases. Pathology, pathogenesis, and 
pathophysiology William MacNee 
 
Oxidative stress. 
The oxidative burden is increased in COPD. Sources of oxidants include cigarette smoke and 
reactive oxygen and nitrogen species released from the attracted inflammatory cells. This creates 
an imbalance in oxidants and antioxidants resulting oxidative stress. Many markers of oxidative 
stress are increased in stable COPD and are further increased in exacerbations of the disease. 
Oxidative stress may lead to inactivation of antiproteases or stimulation of mucous production. It 
may also increase inflammation by enhancing transcription factor activation (such as nuclear 
factor B) and hence gene expression of pro-inflammatory mediators.  Pathology, pathogenesis, 
and pathophysiology William MacNee 
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Pathophysiology  
The above pathogenic mechanisms result in the pathological changes of the disease. These in 
turn activate physiological abnormalities—mucous hypersecretion and ciliary dysfunction, 
airflow obstruction and hyperinflation, gas exchange abnormalities, pulmonary hypertension and 
systemic effects. 
Mucous hypersecretion results in a chronic productive cough. This is a characteristic of chronic 
bronchitis and thought not necessarily associated with airflow obstruction, not all COPD patients 
have symptomatic mucous hypersecretion. Hypersecretion happens due to squamous metaplasia, 
increased numbers of goblet cells and increased size of bronchial submucosal glands in response 
to chronic irritation by noxious particles and gases. 
Ciliary dysfunction is due to squamous metaplasia of epithelial cells and comes as a result in  
abnormal mucociliary escalator or difficulty in expectorating. Pathology, pathogenesis, and 
pathophysiology William MacNee 
 
Clinical features 
Presentation. The main symptoms of COPD are dyspnoea (exertional dyspnoea is the most 
common early symptom), chronic cough and sputum production. These symptom may be under- 
reported by the patients. Less often symptoms are wheezing and chest tightness. Symptoms 
usually start in mid-life and are slowly progressive.  
Patients with COPD can present with chronic daily respiratory symptoms, recurrent acute 
exacerbations. They may present with relatively little respiratory complaints but with an 
extremely sedentary lifestyle due to the exertional dyspnea (Global Initiative for Chronic 
Obstructive Lung Disease, 2017). Chronic inflammation causes structural changes, narrowing of 
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the small airways and destruction of the lung parenchyma that leads to the loss of alveolar 
attachments to the small airways and decreases lung elastic recoil. 
 
Diagnosis. Spirometry is required to establish the diagnosis of COPD. A post-bronchidialtor 
FEV1/FVC ratio less than 0.7 confirms the presence of persistent airflow limitation. In the 
absence of an alternative explanation for the symptoms and airflow limitation, the diagnosis is 
COPD (Global Initiative for Chronic Obstructive Lung Disease, 2017). 
 
2.2.2. EPIDEMIOLOGY  
COPD is a common disease, with a highest prevalence among those over 60 years old, with an 
estimated prevalence worldwide of 10% (Halbert et al., 2006). An increased prevalence is 
estimated amongst men, although the number of women who have COPD has been rising over 
recent years. A severe genetic form is seen in younger females. 
COPD is currently the 4
th
 leading cause of death worldwide (Lozano et al., 2012) but is projected 
to be the 3
rd
 by 2020 (Mathers & Loncar, 2006). 
Aetiology. The most commonly encountered risk factor for COPD is cigarette smoking. Other 
types of tobacco and marijuana are also encountered risk factors. Occupational exposure to dust 
and chemicals and indoor air pollution from biomass fuel burning have been seen to increase risk 
of developing COPD. 
The best known genetic risk factor is hereditary deficiency of alpha-1 antitriprysin. These 
patients typically develop emphysema earlier; other genetic risk factors are also thought to 
contribute to COPD (Global Initiative for Chronic Obstructive Lung Disease, 2017). 
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2.2.3. METHODS OF TREATMENT 
 
2.2.3.1. MEDICATIONS 
Smoking cessation has the greatest impact on the evolution of the disease. The pharmacologic 
treatment of stable symptomatic COPD includes bronchodilators (beta agonists, anticholinergics, 
teophylline) alone or in combination with inhaled glucocorticoids +/- phosphosterase 4 
inhibitors.  
Pulmonary rehabilitation and oxygen therapy in patients with chronic hypoxemia at rest is also 
important. In selected patients with severe emphysema lung volume reduction, surgery 
(removing an area of emphysematous lung to allow the rest of the lung to expand better when 
breathing) is proposed. 
Oxygen therapy, short-acting bronchodilators and systemic corticosteroids are the main 
treatments for exacerbations. In specific situations antibiotics are used (Global Initiative for 
Chronic Obstructive Lung Disease, 2017; Celli et al., 2004). 
The natural history and prognosis of COPD are variable but there is usually a slow gradual 
decline with increasing symptoms. The reduction in life expectancy depends on the severity of 
the disease (Shavelle et al., 2010). 
 
Differential diagnosis. The finding of irreversible airflow limitation on spirometry in a patient 
with risk factors (smoking history) and clinical symptoms of COPD is diagnostic. A chest 
radiograph can help to exclude other possible diagnosis as heart failure or interstitial lung 
disease. 
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Asthma, bronchiectasis and scarring from previous tuberculosis need to be considered in the 
differential diagnosis. To be taken into account is the fact that these can also occur concomitant 
with COPD (Global Initiative for Chronic Obstructive Lung Disease, 2017; Halbert et al., 2006). 
       
2.2.3.2. DIET - OTHER THERAPEUTIC APPROACHES 
There is evidence to suggest that a “western” style dietary pattern increases the risk of asthma in 
children, has worse outcomes for adults with asthma, and is related to COPD risk. 
 
Fruit and Vegetables. Fruit and vegetable intake has been investigated for potential benefits in 
association with respiratory conditions due to their nutrient profile consisting of antioxidants, 
vitamins, minerals, fibre and phytochemicals. In adults, Grieger et al. (2013) discussed the 
heterogeneous nature of the data describing fruit and vegetable intake and lung function, with 
one study showing no effect on lung function of higher fruit and vegetable intake over 10 years 
(Butland et al., 2000), yet in another study, increased fruit intake over 2 years was associated 
with increased FEV1 (Butland et al., 2000), while another study showed that a large decrease in 
fruit intake over 7 years was associated with decreased FEV1 (Carey et al., 1998). Increased fruit 
and vegetable intake may be protective against COPD development, with consumption of a 
“prudent” diet, including increased fruit and vegetables, being protective against lung function 
decline (Shaheen et al., 2010). Two randomized controlled trials (RCT’s) manipulating fruit and 
vegetable intake have been conducted in COPD. A 12 week study showed no effect of a high 
fruit and vegetable intake on FEV1, systemic inflammation or airway oxidative stress (Baldricket 
al., 2012). However, a 3-year study in 120 COPD patients revealed an improvement in lung 
function in the high fruit and vegetable group compared to the control group (Keranis et al., 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:03:26 EEST - 137.108.70.13
Σ ε λ ί δ α  | 43 
 
43 
 
2010), suggesting that longer term intervention is needed to provide a therapeutic effect. There is 
considerable evidence to suggest that a high intake of fruit and vegetables is favorable for all life 
stages of asthma and evidence is emerging which suggests the same in COPD.   
 
Omega-3 Fatty Acids and Fish. Omega-3 polyunsaturated fatty acids (PUFA) from marine 
sources and supplements have been shown to be anti-inflammatory through several cellular 
mechanisms including their incorporation into cellular membranes and resulting altered synthesis 
of eicosanoids (Thies et al., 2001). 
Omega-3 PUFA may have positive effects in COPD, as higher levels of DHA in serum were 
found to decrease the risk of developing COPD (Shahar et al., 1999). Experimental studies in 
humans with COPD, including supplementation with omega-3, found lower levels of TNF-α (De 
Batlle et al., 2012) and improved rehabilitation outcomes (Broekhuizenet al., 2005), though no 
improvements were seen in FEV1. 
 
Antioxidants. Dietary antioxidants are an important dietary factor in protecting against the 
damaging effects of oxidative stress in the airways, a characteristic of respiratory diseases (Wood 
et al., 2003). Oxidative stress caused by reactive oxygen species (ROS) is generated in the lungs 
due to various exposures, such as air pollution, airborne irritants and typical airway 
inflammatory cell responses (Kelly, 2005). Also, increased levels of ROS generate further 
inflammation in the airways via activation of NF-κB and gene expression of pro-inflammatory 
mediators (Rahman, 2003). Antioxidants including vitamin C, vitamin E, flavonoids and 
carotenoids are abundantly present in fruits and vegetables, as well as nuts, vegetable oils, cocoa, 
red wine and green tea. Dietary antioxidants may have beneficial effects on respiratory health, 
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from influences of the maternal diet on the fetus, and intake in children through to adults and 
pregnant women with asthma and adults with COPD. Finally, α-tocopherol (a form of vitamin E) 
helps cells maintain integrity of membrane fatty acids, by inhibiting lipid peroxidation (Grieger 
et al., 2013). 
 
Metabolic phenotypes and nutritional risk profile in COPD 
Large population studies have shown that the age-standardised rate of death from any cause was 
lowest among participants with a BMI of 22.5–24.9 kg/m2 and of 20–25 kg/m2 in analyses made 
restricted to nonsmokers (Berrington de Gonzalez et al., 2010; Whitlock et al., 2009). In patients 
with moderate to severe airflow obstruction, a BMI <25 kg/m
2
 was associated with constant high 
mortality risk relative to overweight or obese patients (landbo et al., 1999; Schols et al., 1998; 
Lainscak et al., 2011). This ‘‘obesity paradox’’of increased BMI in COPD, could be related to 
the direct effect of adipose tissue on lung mechanics (Ora et al., 2011). It might also be an 
epiphenomenon of other, yet unknown diseases that lead to both a reduced mortality risk and 
preserved fat mass and/or fat free mass (FFM). It is not yet clear whether it is excessive fat or 
preserved FFM that contributes to the survival advantage in COPD, as it is proven that a low fat 
free mass index (FFMI) (<10th percentile), independent of BMI and fat mass, is a strong 
predictor of mortality (Schols et al., 2005). Prevalence of underweight in COPD increases with 
disease severity (Schols et al., 2005) and is directly associated with the emphysema (Engelen et 
al., 1999). Normal to overweight patients, that present a low FFMI have a proportionally high fat 
mass index. Furthermore, a redistribution of fat mass from subcutaneous to visceral adipose 
tissue has been associated with increased cardiovascular risk in mild to moderate COPD (van den 
Borst et al., 2012). Underweight patients or with low FFM are more prone to loss of bone 
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mineral density (BMD) than overweight patients (Bolton et al., 2004). DEXA is used for 
combined screening of osteoporosis, FFM and fat mass. Distinction between abdominal visceral 
and subcutaneous fat mass requires advanced imaging technologies (e.g. computed tomography 
and magnetic resonance imaging), but a clinically useful estimate can be derived by DEXA.  
 
Pathophysiology of abnormal body composition and targets for nutritional intervention 
Understanding the pathophysiology of muscle loss and adiposity in COPD is important for the 
development of targeted nutritional interventions to address specific metabolic phenotypes. We 
present a summary relevant to alterations in nutritional status and possible nutritional 
intervention. For a detailed account of skeletal muscle wasting in COPD, the reader is directed to 
the recently updated American Thoracic Society/ERS statement on lower limb muscle 
dysfunction in COPD (Maltais et al., 2014). 
 
TABLE 1.   Metabolic phenotypes in COPD patients (Schols et al., 2014). 
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Fat loss 
Loss of body weight and fat mass happens when energy expenditure in grater than energy intake. 
Eating per se, can adversely affect haemoglobin saturation and increase dyspnoea in patients 
with severe COPD (Schols et al., 1991a). Ageing is a contributing factor to reduced dietary 
intake in COPD due to loss of taste, poor dentition, dysphagia, poor chewing and swallowing 
ability, poor appetite, or food aversion, as well as the presensce of social problems (e.g. living or 
eating alone, or poverty) and inability to self-feed (Gronberg et al., 2005). Anorexia is not the 
primary trigger of energy unbalance in clinically stable disease, as generally, a normal appetite to 
increased dietary intake is seen in underweight patients (Goris et al., 2003; Schols et al., 1991b). 
While the normal response to semi-starvation is a reduced metabolic rate and depressed protein 
turnover, weight-losing in COPD patients may display elevated resting energy expenditure and 
generally increased whole-body protein turnover (Kao et al., 2011). In addition to an increased 
cost of ventilation due to abnormal pulmonary mechanics, a higher energy cost is required for 
muscular contraction (Layec et al., 2011), fact that may contribute to decreased mechanical 
efficiency of lower limb exercise (Baarends et al., 1997a) and elevate daily energy requirements 
in certain COPD patients (Baarends et al., 1997b). Furtheremore, weight gain after lung volume 
reduction surgery was proved as a result of better lung function and reduced work of breathing 
(Kim et al., 2012). Collectively, this causes a hypermetabolic state that may contribute to weight 
loss. After hyperalimentation adverse effects were observed in carbohydrate supplementation in 
COPD due to increased carbon dioxide production, resulting from carbohydrate oxidation 
loading ventilation but have not been substantiated in more recent studies (Efthimiou et al., 
1992); this is, in practice, unlikely to happen with oral nutrition and can easily be avoided by 
smaller meal portions well spread over the day. 
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Muscle loss 
Muscle mass is determined by the net balance of muscle protein synthesis and protein 
breakdown. An increased muscle protein degradation rate was present in cachectic COPD 
patients characterised by low BMI and low FFMI (Rutten et al., 2006). After analyses of the 
effector pathways of protein degradation a consistent elevation of components of the ubiquitin 
26S proteasome system (Langen et al., 2013) and enhanced autophagy (Guo et al., 2013) were 
observed. 
Furtheremore, distal protein synthesis signalling cues (insulin-like growth factor I and phospho-
Akt expression levels) are mainly stable (Langen et al., 2013). In cachectic patients, stimulating 
protein synthesis more proximally with nutritional intervention to balance elevated proteolysis 
may contribute to muscle mass maintenance in the presence of increased protein turnover, fact 
that is taking for granded that there is no impairment in protein synthesis signalling (i.e. its 
responsiveness to catabolic triggers), and requires further research (Jonker et al., 2014). 
Presuming a positive energy balance, nutritional intervention should target at provision of 
sufficient amino acids to support protein synthesis signalling and could evoke a compensatory 
response to increases in proteolysis cues (Jonker et al., 2014). Stimulation of protein synthesis 
depends on the availability of amino acids in the circulation. COPD patients with low FFM have 
low plasma levels of branched-chain amino acids (BCAAs) (Engelen et al., 2000). BCAAs, 
particularly leucine, are stimulators of muscle protein synthesis. The extraction of amino acids 
by the intestine has a critical influence in availability to peripheral tissues. Lower splanchnic 
extraction associated with an enhanced anabolic response to a protein meal (Engelen et al., 2012) 
was observed in sarcopenic patients with COPD, which probably is related to compromised 
intestinal function (Rutten et al., 2013). Supplementation of soy protein with BCAAs improoved 
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inter-organ metabolism in the muscle compartment in COPD (Engelen et al., 2007). The 
emphysematous phenotype exhibited a blunted whole-body protein turnover after acute exercise 
and so, further research is required to investigate if the anabolic potential of high-quality protein 
is less in chronic respiratory failure or in the cachexia-susceptible emphysematous phenotype 
(Engelen et al., 2003). Increased levels of oxidative stress have been consistently reported in the 
skeletal muscle of COPD patients. Muscle biopsy analyses have prooved activation of FOXO 
(fork head box O), MAPK (mitogen-activated protein kinase) and NF-kB (nuclear factor, k-light 
chain activator of B-cells) in signalling pathways sensitive to oxidative stress and involved in 
muscle mass regulation. MAPK and NF-kB signalling are also introdused by inflammation and 
increased inflammatory cell infiltration, with a result of pro-inflammatory cytokine expression. 
These catabolic pathways or upstream triggers such as oxidative stress and inflammation may be 
suitable targets for nutritional modulation (Langen et al., 2013). 
 
Bone mineral density loss 
Osteoporosis is a skeletal disease characterised by loss of bone mass and microarchitectural 
deterioration resulting in bone fragility and high susceptibility to fracture (Sambrook & Cooper, 
2006). Hip fractures are directly related to falls, while vertebral fractures often occur silently and 
are the result from routine activities such as bending or lifting causing hospitalisation and excess 
mortality. In COPD patients vertebral and rib cage fractures may lead to increased kyphosis and 
reduced rib cage mobility resulting further reduction in pulmonary function. Prevalence data of 
coincidence of COPD and osteoporosis vary from 5% to 60% depending on the diagnostic 
methods used (Lehouck et al., 2011). A reason for this association is the presence of common 
risk factors such as ageing, smoking, underweight, sarcopenia and physical or functional 
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limitation. Furtheremore, systemic inflammation, use of systemic corticosteroids and the high 
prevalence of vitamin D deficiency,  are frequently observed in more severe stages of COPD, 
and contribute to a further loss of bone and muscle mass (Lehouck et al., 2011; Graat-Verboom 
et al., 2009). 
Studies also suggest that emphysema represents a particular phenotype as a result of 
musculoskeletal impairment but the underlying mechanisms remaine unclear (Bon et al., 2011; 
Makita et al., 2007; Ohara et al., 2008). Bone tissue is continuously renewed throughout life, 
with a reaching peak bone mass at the age of 25 to 30 years and an expected bone formation 
balance back to resorption with an annual loss of 0.5–1%. On the cellular level, remodelling of 
bone consists in an interaction between osteoblasts, cells producing osteoid protein matrix that 
subsequently mineralises, and osteoclasts, which absorb bone and release calcium back from its 
stores, which is regulated by NF-kB and its ligand (receptor activator of NF-kB (RANK)/RANK 
ligand (RANKL) system) expressed on the surfaces of both cell types. On this pathway Vitamin 
D plays a key role in the regulation of calcium and bone homeostasis with other factors, although 
several proinflammatory cytokines also present a regulating role. Production of parathyroid 
hormone is triggered by low 25-hydroxyvitamin D (25-OHD) levels, which, through the 
activation of the RANK/RANKL system, activates osteoclasts into bone resorption, calcium 
release and subsequent stabilisation of blood calcium levels (Lips, 2001). Associations between 
low 25-OHD levels and BMD have been shown in different populations, as well as in COPD 
patients (Graat-Verboom et al., 2009; Franco et al., 2009). Sufficient intake of vitamin D and 
calcium, as well as lifestyle modifications (increased physical activity, spending more time 
outside, smoking cessation and limited alcohol use), composes the basis of all prevention and 
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treatment strategies of osteoporosis, as low 25-OHD levels are also associated with muscle 
weakness and increased risk of falls (Rachner et al., 2011). 
 
Adiposity 
In patients with advanced disease and sarcopenia and cachexia as risk factors, respiratory failure 
is the most common cause of death. COPD patients with mild-to-moderate disease in which 
adiposity is a lifestyle-induced risk factor, the primary cause of death is ischaemic cardiovascular 
disease (McGarvey et al., 2007). There is strong evidence that abundance of adipose tissue in 
COPD patients is a significant contributor to the systemic inflammatory load (van den Borst et 
al., 2011). Abdominal visceral fat is more strongly associated with cardiovascular risk, while 
subcutaneous fat could be related to a higher inflammatory capacity. In mild to moderate, 
nonobese COPD patients compared with controls, a fat redistribution was shown towards more 
abdominal visceral fat, despite measured comparable total fat mass (van den Borst et al., 2012). 
To what extent this redistribution reflects unhealthy lifestyle or is disease-induced is yet unclear 
and remains for further research whether the two act synergistically (van den Borst et al., 2013). 
The fact that obese COPD patients have increased dyspnoea at rest and poorer health status 
related to normal-weight patients, while static lung hyperinflation is reduced, seems to be 
unrelated to the severity of disease (Ora et al., 2011). The coexistance of obesity and COPD has 
an effect on exercise tolerance that seems to depend on the type of exercise (weight-bearing 
versus non-weight-bearing). While peak cycling capacity is preserved in obese COPD patients 
compared with nonobese patients and the dyspnoea ratings are systematically lower during 
cycling in obese patients, the 6-min walk distance (6MWD) is lower and the degree of fatigue is 
higher in obese patients (Bautista et al., 2011). There are no systemical studies in the 
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investigation of the effects of weight loss interventions on adiposity, functionality and systemic 
inflammatory profile in COPD patients. Weight maintenance after a small weight loss period is 
reported as a challenge in all risk populations, while even modest reductions in weight may 
reduce the cardiovascular disease risk through improvements in body fat distribution (Chaston et 
al., 2008). Aerobic exercise training is known to improve insulin sensitivity, induce 
mitochondrial biogenesis in skeletal muscle and induce loss of visceral fat mass. A dietary 
intervention combined with aerobic exercise may have best results (van den Borst et al., 2013). 
Efficacy of this approach may be limited in advanced COPD because of ventilatory restraints on 
exercise intensity. 
As an adjunct, administation of bioactive nutrients (e.g. polyphenols, polyunsaturated fatty acids 
(PUFAs) and vitamin B3) could be helpfull to boost muscle mitochondrial metabolism and limit 
visceral fat accumulation (Schols et al., 2013), but this requires similar clinical trials in COPD in 
the future. 
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Figure 1. Abnormal metabolic phenotypes and related nutritional risk in chronic obstructive 
pulmonary disease. a) healthy (reference) with: 1) normal-high rsolution computer tomography 
of lung tissue; 2) graphic presentation of magnetic resonance imaging (MRI) with quadriceps 
muscle (red) and adipose tissue (yellow;) 3) normal quadriceps muscle cross section area and 
fibre type distribution (red: type I; pink: type IIA; white: type IIX); 4) healthy arterial blood 
vessel; 5) Normal bone tissue; and 6) graphic representation of MRI image of abdomen showing 
visceral and subcutaneous adipose tissue (yellow). b) Cachexia is often linked to 1) emphysema 
and hyperinflation, with 2) loss of skeletal muscle mass combined with 3) muscle fidbre atrophy, 
and a type I to II shift leading to decreased skeletal muscle function, 5) osteoporosis and 6) 
wasting of fat mass. c) Obesity is often linked to 1) chronic bronchitis with 6) increased 
subcutaneous and visceral adipose tissue, and 4) arterial stiffness and increased cardiovascular 
risk. d) Sarcopenia and hidden obesity is not clearly linked to a specific pulmonary phenotype, 
but is characterized by 2) loss of skeletal muscle mass combined with 3) muscle fibre atrophy 
and type I or II shift leading to decreased muscle function, preservation of fat mass but 
redistribution of adipose tissue towards increased 6) visceral adipose tissue, 4) arterial stiffness 
and increased cardiovascular risk. 
 
Acute exacerbations 
Weight loss and wasting of muscle and bone tissue may happen during severe acute 
exacerbations requiring hospitalisation, due to conguity of catabolic stimuli including 
malnutrition (Varmeeren et al., 1997), physical inactivity (Ehsan et al., 2013), hypoxia, 
inflammation (Creutzberg et al., 2000) and systemic glucocorticoids (Saudny-Unterberger et al., 
1997). 
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Practical difficulties due to breathlessness or treatments such as ventilation may reduse energy 
intake. Moreover, impaired responsiveness to signalling cues of muscle regeneration and protein 
synthesis may delay recovery and diminiss possibility of readmission (Pouw et al., 2000). In 
acute respiratory exacerbations phase, the expected loss of appetite results in elevated systemic 
levels of the appetiteregulating hormone leptin and pro-inflammatory cytokines (Vermeeren et 
al., 1997; Creutzberg et al., 2000). In cases of hospitalisations an additional opportunity for 
detailed nutritional assessment could be considered as well as an oppostunity of longer term 
nutritional management, as they represent a period of heightened ‘‘nutritional risk’’ that may 
require intensive nutritional therapy (Lainscak et al., 2013). This is to be established with similar 
clinical trials in COPD in the future. 
 
Dietary management and nutritional supplementation 
Nutrient or micronutrient randomised clinical trials face specific obstacles, some of which are 
difficult to resolve, such as having a placebo or blinding of food. Nutrients, due to their 
multiplemetabolic impact, present difficulties in choosing a primary outcome and a 
determination of sample. Research on single foods is complex because it exploits a big number 
of bioactive compounds acting on a very lerge network of interacting processes. 
 
Treatment of weight loss in COPD 
A COPD patient in a negative energy balance and losing weight will require increased energy 
intake, as an additional reduction in energy expenditure is undesirable. Suitable energy- and 
proteinenriched diet can be achieved by many small portions throughout the whole day 
(Broekhuizen et al., 2005). The energy and protein-enriched diet should have a higher fat content 
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(45% of total energy) in healthy individuals. Due to high proportion of fat requirements, a 
consideration is raised about the quality of the fat. It is recommended currently by guidelines that 
protein should provide 20% of the total energy intake. 
Many products can be used to increase energy and protein content in the different small meals 
(Weekes et al., 2009). A dietician is able to create energy- and protein-enriched diet taking into 
account each subject’s eating habits. At low energy intakes, it is hard to fulfil the expectd needs 
for vitamins, minerals or other elements. If this is the case, oral nutritional supplements (as 
powders, puddings or liquids) can be used. In weight-losing and underweight COPD patients the 
rationale is to support nutrition status and to maintain or increase energy availability and muscle 
protein synthesis. Randomised clinical trials investigating the clinical efficacy of which are 
generally small and initial meta-analyses revealed small estimates of effect only. The Cochrane 
review by FERREIRA et al. (Ferreira et al., 2012) was recently updated and now includes 17 
trials (632 participants) of o2 weeks of nutritional support. The post-treatment values were 
pooled for all outcomes and the changes from baseline scores (change scores) were pooled for 
primary outcomes. The updated review incorporated the Grading of Recommendations 
Assessment, Development and Evaluation (Atkins et al., 2004) approach aswell, to determine the 
quality of the evidence (i.e. risk of bias of included studies, inconsistency of results, indirectness 
of the evidence, imprecision of the data and possible publication bias). The increased body of 
evidence gives a clear picture of the overall effects of nutritional supplementation and the impact 
in each specific COPD subgroup. Moderate-quality evidence (due to mixed risks of bias) 
suggests that nutritional supplementation promotes weight gain among patients with COPD, 
especially if cahectic. There was important improvement in anthropometric measures (FFM, 
mid-arm muscle circumference and triceps skin folds) (fig. 3), 6MWD, respiratory muscle 
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strength (maximal inspiratory and expiratory pressures) and overall health-related quality of life 
as valued by the St George’s Respiratory Questionnaire in undernourished patients with COPD. 
The increase in 6MWD reached the minimal clinically important difference in severe COPD 
(Puhan et al., 2011; Polkey et al., 2013). The results of recent systematic reviews and meta-
analyses now suggest that nutritional supplementation should be incorporated to the management 
of undernourished patients with COPD. Five out of 17 trials included in the updated meta-
analysis (Ferreira et al., 2012), had nutritional supplementation combined with exercise. It is 
likely that the benefits of supplementation will be maximised if combined with exercise, 
although based on the current literature, the effects of nutrition and exercise cannot clearly be 
distinguished, which is a subject for future research. 
 
Nutrition as ergogenic aid 
Nutrition is important for the enhancement of performance and training and has long been 
recognised in the fields of sports and athletics. The benefits of ensuring adequate carbohydrate 
and protein intake (depending on the athletic discipline) in optimising performance are today 
known (van Loon, 2014) and there is evidence that some specific nutrients (e.g. creatine, PUFAs 
and nitrate) may enhance physical performance (Devries & Phillips, 2014; van de Bool et al., 
2012; Mickleborough, 2013; Cermak et al., 2012). Enhancing physical performance is a key 
therapeutic goal in COPD. Therefore, there are reasons for hypothesising that nutritional 
intervention might improve performance in this population or enhance the outcome of exercise 
training, something that is of proven clinical and physiological benefit in COPD. 
Aerobic exercise training is of established efficacy in COPD thus it remains uncertain whether 
the benefit is comparable to similar aged healthy subjects. Moreover, lower limb muscles in 
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COPD are characterised by a decreased proportion of type I muscle fibres associated with 
decreased levels of muscle oxidative metabolic markers and nutrient sensing regulators of 
cellular energy state (e.g. peroxisome proliferator-activated receptor (PPAR)-c coactivator 1, 
PPARs, AMP-activated kinase and sirtuins) (Schols, 2013). 
Task Force members (van de Bool et al., 2012) have recentnly reviewed exercise training with 
nutritional therapies in COPD. A variety of interventions including carbohydrate and fat-rich 
supplements (Steiner et al., 2003), essential amino acids (Baldi et al., 2010), whey protein (rich 
in BCAAs) (Sugawara et al., 2011), creatine (Deacon et al., 2008; Fuld et al., 2005; Faager et al., 
2006) and PUFAs (natural ligands of PPARs) was reviewed (Broekhuizen et al., 2005). In the 
literature involved there is no homogenicity is considering the nature of the intervention, the 
populations enrolled and the exercise outcomes that were studied. The studies were 
underpowered or single-centre investigations. The first investigations involved fat-rich 
supplements but did not suggest a performance advantage in the intervention groups, while later 
studies using a carbohydrate-rich supplement and PUFAs suggested the outcome or exercise 
training might be enhanced in selected patients (Steiner et al., 2003; Broekhuizen et al., 2005). 
Potential benefits of whey protein and carnitine have been studied, but with no insufficient 
statistical power for wider conclusions to be drawn. A systematic review and meta-analysis of 
three trials that tested the effect of creatine supplementation during exercise training in COPD 
found no consistent positive effect (Al-Ghimlas & Todd, 2010). In a group of COPD patients, 
with overall non-wasted protein and carbohydrate supplementation after resistance exercise they 
did not augment functional or molecular exercise responses (Constantin et al., 2013). Whether 
nutritional support can help the performance outcomes of exercise training and pulmonary 
rehabilitation remains largely unanswered. 
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Cost-effectiveness issues 
In other countries nutritional counselling and oral nutritional supplements compete with other 
treatments for a part of the publicly funded healthcare budget; something that is not the case in 
our country. It is thought important to assess their cost-effectiveness. There are no data on the 
economic implications of these interventions in COPD. Numerous studies, however, reported on 
the association between nutritional status and healthcare utilisation, focusing on hospitalised 
patients. They showed that being undernourished in COPD is likely to be associated with longer 
hospitalization (Giron et al., 2009l Gupta et al., 2010), a higher probability of being readmitted 
(Pouw et al., 2000; Hallin et al., 2006) and an increase in healthcare utilization (odencrants et al., 
2008) in comparison with normally nourished patients. Three randomised controlled trials in 
COPD investigated the effects of nutritional supplementation on healthcare utilisation and their 
costs (Weekes et al., 2009; van Wetering et al., 2010; Edington et al., 2004). Two studies did not 
find a difference in hospital admissions. It is very probable that in these studies, the duration of 
follow-up of 6 months was too short to detect an effect on healthcare utilisation. The only full 
economic evaluation, which was a pre-specified subgroup analysis of the 24-month 
Interdisciplinary Community-Based COPD Management Program trial, comparing usual care in 
COPD with nutritional rehabilitation in patients with low muscle mass, found a significant 
reduction in hospital costs (van Wetering et al., 2010). The mean total COPD and non- COPD 
related costs per patient after 2 years were J12 830 for the intervention group and J14 025 for the 
usual care group, resulting in net savings of J1195 (95% CI -7905–5759). Compared with the 
usual care group, the intervention group had a significant decrease in hospitalisation costs J-4724 
(95% CI -7704– -1734). Because of these net cost savings, no cost-effectiveness ratio was 
calculated. There is a need for more cost-effectiveness studies of nutritional counselling and 
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supplementation to support decision making about reimbursement of these additional 
interventions in COPD. There are several possibilities. There is the conventional approach of 
designing randomised clinical trials in which the additional costs and benefits of adding a 
nutritional intervention to usual care are investigated. Because usual care is a multimodal 
pulmonary rehabilitation programme or disease management programme that already includes 
nutritional counselling, the newly designed trials should focus on assessing the added value of 
the oral supplements and/or the long-term nutritional counselling. Because of the current lack of 
any cost-effectiveness data, these trials could use patients from different target groups including 
end-stage COPD patients with both muscle loss and weight loss (cachexia) as well as weight-
stable COPD patients with muscle wasting (sarcopenia). More risk factors should be investigated 
as weight change, BMI and FFMI, and the risk of COPD exacerbations and hospitalizations, in 
observational studies. Such data could be used in cost-effectiveness modelling studies to 
simulate potential long-term effects of changes in weight, BMI and FFM on health status, 
healthcare utilisation and costs. Cost should be determined as it seems that the costs of 
nutritional intervention in sarcopenic COPD patients are likely to precede the benefits by far. 
Vitamin D deficiency and insufficient intake of vitamins with antioxidant capacity (vitamins A, 
C and E) have been reported in COPD. Vitamin D has an important role in bone and calcium 
homeostasis but effects are also anti-inflammatory, anti-infectious and anti-tumoural, as well as 
neuromuscular improvements, have been attributed to vitamin D [112]. Vitamin D status is 
assessed by the measurement of serum levels of 25-OHD, a precursor of  the active hormone., 
vitamin D status is an independent predictor of all-cause mortality, upper airway respiratory 
infections and pulmonary function, in the general population. For COPD, evidence is conflicting 
on whether 25-OHD levels correlate with lung function decline, infectious exacerbations and 
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muscular function [113–116]. Vitamin D level is determined by the synthesis capacity of the 
skin, the hours of sun (ultraviolet) exposure, possible genetic variation in key enzymes of the 
involved pathway and supplemental intake in food. In COPD, vitamin D deficiency possibly 
occurs because of smoke-induced skin ageing, reduced outdoor activity and/or low-quality 
dietary intake. It is internationally accepted that vitamin D deficiency (25-OHD levels ,20 
ng?mL-1) is highly prevalent in COPD and increases with disease severity. Recent prospective 
epidemiological evidence associates vitamin D deficiency with an increased incidence of COPD 
and a more rapid decline of pulmonary function in subjects with COPD [117]. The higher 
prevalence in more advanced COPD and in nutritionally depleted states suggests that screening 
for vitamin D deficiency may be of value in these populations. Screening for vitamin D 
deficiency may restrict to vitamin D deficient patients, in whom the beneficial effects on the 
bones and fall prevention, especially if combined with calcium intake, are proven. Daily intakes 
in addition to a minimal amount of ultraviolet radiation exposure vary with age but a dose of 800 
IU with 1 g calcium is considered to be largely sufficient. The possibility of highdosage 
supplementation to obtain other than calcaemic effects, including lung function decline and 
COPD exacerbations, needs further exploration [118]. 
Insufficient dietary habits of intake of fresh fruits and vegetables may result in deficiency of 
vitamins with antioxidant capacity. On the other hand, long-term supplementation with vitamin E 
has been shown to reduce the risk of COPD [119] although there is no evidence on the positive 
effects of additional vitamin intake on clinical outcome in a COPD population. Smoking and 
lung inflammation in COPD are known to cause significant oxidative stress, so the reduction of 
the antioxidative capacity may have negative effects on the course of COPD. 
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Large, population-based epidemiological studies have shown that a poper diet is associated with 
better pulmonary function, less lung function decline and reduced risk of COPD [120–122]. 
Interestingly, intake of dietary fibre has been largely associated with reduced COPD risk, better 
lung function and reduced respiratory symptoms [123]. Three studies have reported hight 
prevalence of developing COPD when frequent or high consumption of cured meats [120, 124, 
125]. A study has extended this association to include the evolution of the disease, revealing that 
high cured meat consumption is linked to a higher risk of rehospitalization in COPD [126]. 
Finally, even rarely assessed in clinical practice, iron deficiency occurs often in COPD patients, 
caused by several factors including systemic inflammation, malabsorption of iron from the gut, 
renal failure (as a consequence of concomitant chronic kidney disease or diabetes mellitus), and 
medications such as angiotensin-converting enzyme inhibitors and corticosteroids [127]. The 
above evidence indicates that a well-balanced diet with sufficient intake of fresh fruits and 
vegetables is beneficial to COPD patients, not only for its potential benefits on the lung, but also 
for its proven benefits on metabolic and cardiovascular risk. 
 
Interventional therapy in stable COPD 
Lung volume reduction surgery improves survival in severe emphysema patients with an upper-
lobe emphysema and low post-rehabilitation exercise capacity. 
Bullectomy: In selected patiens bullectomy is associated with decreasd dyspnea, improved lung 
function and exercise tolerance. 
Transplantation in appropriately selected patients with very severe COPD, lung transplantation 
has been shown to improve quality of life and functional capacity. 
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Bronchoscopic interventions in selected patinents with advanced emphysema reduses end-
expiratory lung volume and improves exercise tolerancw, health status and lung function at 6-12 
months following treatment (endobronchial valves and lung coils). 
 
 
 
2.3. NITRATES 
 
The discovery of nitric oxide and its role in vascular biology *S. Moncada & E.A. Higgs 
The Wolfson Institute for Biomedical Research, University College London, Gower Street, 
London WC1E 6BT 
Nitric oxide (NO) is a relative newcomer to pharmacology, as the first paper was published only 
25 years ago. Today its impact is such that to date more than 31,000 papers have been published 
with NO in the title and more than 65,000 refer to it in some way. NO pathway is widespread 
and plays a variety of physiological roles, as proved after the identification of NO with 
endothelium-derived relaxing factor and the discovery of its synthesis from L-arginine. These 
physiological roles include the maintenance of vascular tone, neurotransmitter function in both 
the central and peripheral nervous systems, and mediation of cellular defence. In addition, NO 
interacts with mitochondrial systems to regulate cell respiration and to augment the generation of 
reactive oxygen species, thus triggering mechanisms of cell survival or death. NO inhibits 
platelet aggregation and adhesion and modulates smooth muscle cell proliferation. It has been 
implicated in a number of cardiovascular diseases and every risk factor for these appears to be 
associated with a reduction in endothelial generation of NO. Reduced basal NO synthesis or 
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action leads to vasoconstriction, resulting elevated blood pressure and progressively thrombus 
formation. Adversilly overproduction of NO leads to vasodilatation and resulting  hypotension, 
vascular leakage and disruption of cell metabolism. Appropriate pharmacological or molecular 
biological manipulation of the generation of NO will doubtless prove beneficial in such 
conditions. British Journal of Pharmacology (2006) 147, S193–S201. doi:10.1038/sj.bjp.0706458  
Nitric oxide (NO) is a colorless gas that is not readily soluble in water, while it is highly reactive 
with other elements. NO reacts with oxygen and it may also react by winning an electron and 
forming NO- or losing an electron and forming NO+. The major product of NO after oxidation in 
aqueous solutions is nitrate (Kelm, 1999). 
Nitrate salts are inorganic compounds which can be both natural and synthetic. They are 
synthesized from a nitrogen atom (N) and three oxygen atoms (O) and their chemical symbol is 
NO3.  
Nitrite salts (NO2) are formed from nitrates by reduction (McCasland et al., 1985). 
The inorganic nitrate and nitrite salts are used by humans as preservatives in foods for about 
5000 years. However, a significant public health issue concerning nitrites was raised in the '70s, 
as there was evidence that nitrates and nitrites could be converted in the human body in 
endogenous N-nitrosamines, which are associated with cancer (Bryan, 2006). 
In the early 80s, it was discovered that nitrates and nitrites are also composed endogenously in 
human body via the path of l-arginine-NO. Thus, although researchers used to consider nitrates 
and nitrites as hazardous, it is now emerged that the nitrate-nitrite-NO pathway plays an 
important physiological and therapeutic role in the human body (Lundberg, 2009) (Figure 2). 
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Figure 2. Two main nitric oxide production pathways; L-Arginine-NO pathway and nitrate-
nitrite-NO pathway. 
 
Nitric oxide (NO) is an important component in many physiological processes in the 
transmission of nerve impulses, the mitochondrial respiration, the muscle contraction, but mostly 
in the function of smooth muscle surrounding arteries. NO is responsible for muscle expansion 
and contraction (Vincent, 2010; Brown, 1999; Reid, 2001). 
The bioavailability of NO can affect all the aforementioned functions, especially the endothelial 
function. In chronic diseases, systemic inflammation causes a significant reduction in NO 
bioavailability by affecting substantially the extensibility of the arteries and eventually causing 
severe vascular problems. Patients with diseases like RA and COPD, often present endothelial 
dysfunction and vascular problems, which correlate with the occurrence of cardiovascular 
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disease that is often present in these diseases, and the pathophysiology of each disease (Kelm & 
Schrader, 1990; Davignon and Ganz, 2004; Sattar et al., 2003; Moro et al 2008). 
Foods with high concentrations of dietary nitrates increase NO in serum. It seems that NO has 
anti-inflammatory, antiadhesive and vasodilating properties. In other words, reduced NO 
bioavailability can lead to cardiovascular disease, including atherosclerosis and hypertension 
(Ignarro, 2002). 
Moreover, it has been shown that dietary nitrates have a wide range of beneficial effects such as 
blood pressure reduction, improvent of endothelial dysfunction, and enhancement of 
performance during exercise. Both healthy people and patients with peripheral vascular disease 
that consume a diet rich in nitates may have protection against ischemia, and also reduce arterial 
stiffness (Lidder & Webb, 2013). 
All these data have caused a gradually increase in the reputation of dietary nitrates as a dietary 
supplement during exercise (Jones, 2014) while there is also evidence that they may protect 
against diseases such as gastroenteritis (Powlson et al, 2008). 
 
 
2.1.2. Metabolism of nitrates 
Dietary nitrate (i.e. inorganic nitrate anion NO3-) is rapidly absorbed in the upper 
gastrointestinal tract and distributed through the bloodstream. The biological availability of the 
cooked spinach, raw cabbage and cooked beetroot is almost 100% and reaches the highest 
percentage in blood plasma one hour after consumption. Plasma nitrate levels remain high for 
long enough, as the half-life in plasma is 6.5 hours. Instead, the biological availability of nitrite 
reaches about 95-98% after consuming large quantities (Lidder & Webb, 2013). Most of the 
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ingested dietary nitrate is found in blood plasma, while about 25% of it is absorbed by the 
salivary glands and concentrated in saliva (Jones, 2014) (Figure 3). 
 
 
Figure 3. Nitrate and nitrite metabolism in the human body (retrieved from Kobayashi et al., 
2015). 
 
More than 25% of the ingested NO3- enters the entero-salivary circulation, it is then recycled in 
the blood, collected in the salivary glands and secreted in saliva, where bacteria of the oral cavity 
convert NO3- to NO2-. A part of the NO2- is swallowed and converted in NO within the acid 
environment of the stomach. The remaining NO2- is absorbed in order to increase the NO2- 
concentration in the blood plasma (McKnight et al, 1999; Kelly et al, 2013) (Figure 4). 
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Figure 4. Absorption of dietary nitrate in the gastrointestinal tract. 
 
The metabolism of nitrate was first investigated in animals. Fritsch et al. (1976) showed that a 
specific amount of nitrates are reduced to nitrites by the ileo-cecal microflora in rats. This 
procedure can also be done by the action a nitrate reductase, which can appear in the digestive 
mucosa. Moreover, it has been indicated that there is a possible transition of nitrates in the 
intestinal tract. In 1985, Schultz et al. investigated the transport of nitrates from blood flow in the 
lumen of the colon and their metabolism by intestinal bacteria. They concluded that the colon 
may be responsible for the removal of approximately half the percentage of nitrates that are not 
removed from the body throught the kidneys. 
The endogenous production of nitrates and nitrites in the human body greatly increases their total 
concentration in blood and tissues. NO is endogenously produced by the reduction of L-arginine 
to L-citrulline through three isoforms of NO synthase (NOS) (Ferguson et al, 2013). Nitrites are 
endogenously produced by the oxidation of NO and the reduction of nitrate salts induced by 
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commensal bacteria in the oral cavity and in the gastrointestinal system (Hord et al, 
2009). 
NO can also be produced in the absence of NOS. NOS enzymes are using L-arginine and cellular 
oxygen to produce the free radical NO, which is a key regulator of vascular homeostasis, 
neurotransmission and immune defense. Therefore, NO is a autocrine and paracrine signaling 
molecule (Lundberg et al, 2008). Nevertheless, NO is stabilized in blood and tissues when it is 
oxidized to nitrate and nitrite. Nitrate and nitrite can be considered endocrine molecules which 
are transported in the blood, they are installed in the tissues and can be converted again to NO 
under normal or pathological conditions (Lundberg et al, 2008). 
Studies have shown that there is a variety of enzymes and proteins that can be a catalyst for the 
reduction of nitrates to NO in the blood and tissues. These substances include blood proteins, 
xanthine oxidoreductase, some components of the mitochondrial respiratory chain and other 
reducing agents such as vitamin C and polyphenols that can significantly accelerate the reduction 
of nitrate (Lundberg, 2009). 
As previously mentioned, a significant amount of nitrites are concentrated in saliva. One 
parameter that increases their concentration in saliva is that nitrates are metabolized into nitrites 
and by bacterial microflora located in the posterior surface of the tongue (Pannala et al, 2003). 
Thus, the nitrates are initially reduced to nitrites under the influence of oral bacteria and 
enzymes, and then they can enter the bloodstream. These symbiotic bacteria are necessary for the 
reduction of nitrates in humans, as mammalian cells can not effectively metabolize them. 
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2.2 CONTENT OF NITRATE IN VARIOUS FOODS 
The endogenous synthesis of nitrate includes oxidizing endogenously existing NO and reducing 
the nitrates by symbiotic bacteria in the saliva in the mouth, and gastrointestinal tract. However, 
nitates are also found in foods such as meat and vegetables, and water. The average quantity of 
nitrite that is consumed from diet ranges from 0-20 mg, while the amount of nitrate ranges from 
53-300 mg per day (Machha & Schechter, 2011). Most of the nitrates consumed (approximately 
85%) are derived from vegetables and very little from fruits. Concentration of nitrates in the 
drinking water is <10mg/L in the absence of bacterial contamination, although it can differ 
widely depending on the country and the area of the country of origin (Machha & Schechter, 
2011; Lidder & Webb, 2013). 
Dietary nitrite is primarily derived from the nitrites added to foods as preservatives, especially 
from processed meat products (~ 39%) and toasted food and cereals (~ 34%) (Machha & 
Schechter, 2011; Lidder & Webb, 2013). Dietary nitrites are added in meats to stabilize the 
characteristic red color of these meat products, to give them the characteristic flavor and as a 
preservative to prevent the spores of bacterium Clostridium Botulinum from producing toxin that 
cause fatal illness known as «botulism» (Lidder & Webb, 2013). 
The nitrate content of various vegetables is affected by environmental and genetic factors, and 
cultivation techniques. The main environmental factors include temperature, humidity, sunlight 
and nitrate content of irrigation water (Lidder & Webb, 2013). The nitrate content is also 
influenced by the genotype of the plant, the soil composition, conditions of maturation as well as 
the storage and transport conditions (Hord et al, 2009). 
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2.3 NITRATES AND CHRONIC DISEASES 
There is a growing research interest for the potential benefits of the dietary nitrates on human 
health. Several studies have shown their benefitial effects on the cardiovascular system; they 
improve the condition of the endothelium and protect it from injury after ischemia-reperfusion, 
and they also reduce blood pressure in healthy populations. 
 
Nitrates and cardiovascular health 
Εndothelium plays an important role in maintaining vascular homeostasis, with the release of a 
variety of vascular local mediators, such as endothelium-derived NO. NO is essential for 
maintaining vascular homeostasis because of its actions on both smooth muscle cells and 
circulating blood cells (platelets, monocytes, etc.). Changes in endothelial NO bioavailability can 
lead to endothelial dysfunction, leading to impaired vascular homeostasis and thus in the 
pathogenesis and the clinical expression of a variety of cardiovascular diseases. 
Over the last decades, research has indicated that cardiovascular risk factors (such as 
hypertension, diabetes, menopausal status, aging, lack of physical exercise, smoking, 
inflammation, and dyslipidemia) are associated with endothelial dysfunction due to reduced 
bioavailability of NO in the vascular system. Additionally, endothelial dysfunction causes a 
reduction in vasodilation, which favors the adhesion of platelets and activation of coagulation, 
which could act as a risk factor for cardiovascular events. Thus, restoring or improving the 
bioavailability of NO in the vascular system is of great importance in the treatment of 
cardiovascular diseases. 
There is evidence indicating that dietary nitrates can improve the bioavailability of NO in the 
vascular system, exert vasodilation, inhibit platelet aggregation, and improve cardiovascular 
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health (Moncada S et al., 1991; Cines DB et al.,1998; Quyyumi AA, 1998; Naseem KM. et al., 
2005; Hadi HAR et al., 2005; Ajay M et al.,2006; Hirata Y et al., 2010). 
Atherosclerosis is a diffuse process of the arterial tree that starts in childhood and early adult life 
[1 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 
801±809.]. Its `preclinical' stage may last for decades, during which time athero-sclerotic 
changes progress slowly, eventually causing lumenal stenosis and/or disruptive lesions leading to 
clinical symptoms. Endothelial dysfunction, especially reduction in the bioavailability of 
endothelium-derived nitric oxide, is a key early event in atherogenesis, appearing long before the 
formation of structural athero-sclerotic changes [2 Celermajer DS, Sorensen KE, Gooch VM,  et 
al. Non-invasive detection of endothelial dysfunction in children and adults at risk of 
atherosclerosis. Lancet 1992; 340: 1111±1115, 3 Reddy KG, Nair NR, Sheehan HM, Hodgson 
JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or 
ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 
1994;23: 833±843]. Nitric oxide is released from the endothelial cells in response to increased 
shear stress and certain pharmacologic stimuli [Celermajer DS. Endothelial dysfunction: Does it 
matter? Is it reversible? J Am Coll Cardiol 1997; 30: 325±333]. Nitric oxide may function as an 
endogenous antiatherogenic molecule by maintaining low arterial tone at rest, inhibiting 
leucocyte ± endothelial interactions, attenuating platelet aggregationand inhibiting smooth 
muscle cell proliferation [4 Celermajer DS. Endothelial dysfunction: Does it matter? Is it 
reversible? J Am Coll Cardiol 1997; 30: 325±333]. Therefore the testing of endothelial nitric 
oxide release in humans allows investigation of one particularly important aspect of normal 
arterial physiology. 
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Cardiovascular disease 
Cardiovascular disease (CVD) refers to any disease affecting the cardiovascular system, 
including heart diseases, vascular diseases, diseases of the brain and kidney and peripheral 
arterial disease (Bridget, 2010). There are various risk factors for CVD, such as atherosclerosis, 
hypertension and aging (Dantas et al., 2012). 
According to the World Health Organization (WHO), CVD is the leading cause of death. It is 
estimated that 30% of the total worldwide mortality in 2008 was due to CVD. It is also estimated 
that by 2030, deaths from CVD will reach 23 million each year. Thus changes in lifestyle and 
eating habits that contribute to CVD are of great importance. For example, a study by Webb et 
al. (2008) showed that ingestion of 200 mg dietary nitrate reduced blood pressure, inhibited 
platelet aggregation and improved ischemia-induced endothelial dysfunction in healthy 
individuals. Moreover, apples that are rich in flavonoids and spinach that is rich in nitrates, can 
increase levels of nitric oxide, enhance endothelial function, improve blood pressure, and 
indirectly benefit cardiovascular health (Bondonno et al., 2011). Small changes in diet, such as 
adding foods rich in nitrates, may benefit and protect those at risk for myocardial infarction 
(Kleinbongard et al, 2006). All these results are in accordance with epidemiological evidence 
which indicates that consumption of fruits and vegetables can reduce the risk of CVD. 
 
Diabetes mellitus 
Diabetes mellitus (DM) is a chronic disease that occurs either when the pancreas does not 
produce enough insulin or when the body can not effectively use the insulin that produces. 
Moreover, patients with DM have increased risk of heart disease and stroke, while 50% of them 
die of CVD (especially myocardial infarction and stroke) (Morrish et al., 2001). For that reason, 
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reseach should focus on the prevention and treatment of both microangiopathy and 
macroangiopathy, which are two common long-term complications of DM. 
In a recent study by Gilchrist et al. (2013), supplementation with 7.5 mmol of nitrate per day for 
2 weeks did not result in changes in microvascular or macrovascular endothelial function and 
insulin sensitivity. Although an increase in nitrite and nitrate concentrations in plasma was 
observed, there was no change in blood pressure, endothelial function or insulin sensitivity in 
individuals with type 2 DM. However, in a study by Anderson et al. (2005), platelet response to 
sodium nitroprusside (SNP) and glyceryl trinitrate (GTN) was tested in patients with type 2 DM 
and compared to healthy individuals, with an increase in induced by adenosine diphosphate 
(ADP) platelet aggregation. Platelet aggregation in the fasting state was increased in DM patients 
compared to healthy individuals, while SNP and GTN inhibited ADP aggregation in healthy 
individuals compared to DM patients. In another study, the levels of cyclic guanosine 
monophosphate (cGMP) were found to be significantly lower in DM patients compared to 
healthy individuals. cGMP is responsible for the relaxation of vascular smooth muscle that leads 
to vasodilation and increased blood flow. Moreover, DM patients without late complications had 
significantly higher levels of nitrite/nitrate in comparison to DM patients with complications 
(Farkas et al., 2004). 
 
Reumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic systemic disease that affects the joints, the connective 
tissues, muscles, tendons and fibrous tissue. Its onset is mainly during the most productive years 
of adulthood, between the ages of 20 and 40. RA is a chronic disabling condition often causing 
pain and deformity. The prevalence of RA is between 0.3% and 1%, and is more common in 
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women, with higher prevalence of disease in developed countries. Only 50% of patients with RA 
in developed countries are able to hold a full time job within the first 10 years of the onset of 
disease (Woolf & Pfleger, 2003). 
There is evidence suggesting that RA patients have a high risk of developing coronary heart 
disease (Van Doornum et al., 2002). Indeed, studies confirm the presence of significant 
endothelial dysfunction in RA patients correlated with markers of systemic inflammation. In 
addition to that, some studies indicate that inflammation may be a mediator of endothelial 
dysfunction in those patients (Hurlimann et al., 2002). Inflammation could mediate endothelial 
dysfunction by reduced expression of eNOS (Vallance et al., 1997). NO as mentioned before is 
of great importance for endothelial function. 
 
Chronic Obstructive Pulmonary Disease 
Individuals with COPD have daily minimal excersise as it is limited by multiple factors which 
can result in hypoxemia. Some of these factors include loss of normal lung architecture, impaired 
cardiac function [American ST. ATS statement: guidelines for the six-minute walk test. 
American Journal of Respiratory and Critical Care Medicine. 2002; 166:111–117. [PubMed: 
12091180], abnormal pulmonary blood flow distribution [Bailey SJ, Fulford J, Vanhatalo A, 
Winyard PG, Blackwell JR, DiMenna FJ, Wilkerson DP, Benjamin N, Jones AM. Dietary nitrate 
supplementation enhances muscle contractile efficiency during knee-extensor exercise in 
humans. Journal of Applied Physiology. 2010; 109:135–148. [PubMed: 20466802] and 
peripheral muscle de-conditioning [Bailey SJ, Winyard P, Vanhatalo A, Blackwell JR, Dimenna 
FJ, Wilkerson DP, Tarr J, Benjamin N, Jones AM. Dietary nitrate supplementation reduces the 
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O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans. 
Journal of Applied Physiology. 2009; 107:1144–1155. [PubMed: 19661447].  
Regarding NO, the best known is the classical L-arginine nitric oxide synthase (NOS) pathway 
which is oxygen dependent [Jones AM, Vanhatalo A, Bailey SJ. Influence of dietary nitrate 
supplementation on exercise tolerance and performance. Nestle Nutrition Institute Workshop 
Series. 2013; 75:27–40. [PubMed: 23765348]]. The second is the entero-salivary pathway and is 
oxygen independent. Briefly, nitrate from the diet is rapidly and extensively absorbed in the 
stomach and proximal small intestine with bioavailability approaching 100% [Kelly J, Fulford J, 
Vanhatalo A, Blackwell JR, French O, Bailey SJ, Gilchrist M, Winyard PG, Jones AM. Effects 
of short-term dietary nitrate supplementation on blood pressure, O2 uptake kinetics, and muscle 
and cognitive function in older adults. American Journal of Physiology Regulatory, Integrative 
and Comparative Physiology. 2013; 304:R73–83.]. Nitrate is then concentrated in the salivary 
glands, with concentrations 10 fold greater in saliva than in plasma. Nitrate secreted in saliva is 
reduced to nitrite by facultative anaerobic bacteria on the dorsum of the tongue [Kenjale AA, 
Ham KL, Stabler T, Robbins JL, Johnson JL, Vanbruggen M, Privette G, Yim E, Kraus WE, 
Allen JD. Dietary nitrate supplementation enhances exercise performance in peripheral arterial 
disease. Journal of Applied Physiology. 2011; 110:1582–1591. [PubMed: 21454745]]. On 
swallowing, the acidic environment of the stomach results in NO formation with important local 
effects on gastric function and host defence [Berry MJ, Rejeski WJ, Miller ME, Adair NE, Lang 
W, Foy CG, Katula JA. A lifestyle activity intervention in patients with chronic obstructive 
pulmonary disease. Respiratory Medicine. 2010; 104:829–839. [PubMed: 20347286], Lansley 
KE, Winyard PG, Fulford J, Vanhatalo A, Bailey SJ, Blackwell JR, DiMenna FJ, Gilchrist M, 
Benjamin N, Jones AM. Dietary nitrate supplementation reduces the O2 cost of walking and 
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running: a placebo-controlled study. Journal of Applied Physiology. 2011; 110:591–600. 
[PubMed: 21071588]]. Some nitrite enters the circulation where it acts as a storage pool for 
subsequent NO production [Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre 
type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a 
systematic review and meta-analysis. Thorax. 2007; 62:944–949. [PubMed: 17526675]]. The 
conversion of nitrite to NO is expedited in conditions of acidosis [Larsen FJ, Ekblom B, Sahlin 
K, Lundberg JO, Weitzberg E. Effects of dietary nitrate on blood pressure in healthy volunteers. 
The New England Journal of Medicine. 2006; 355:2792–2793. [PubMed: 17192551]] or 
hypoxemia [Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting in the 
vastus lateralis of patients with COPD is associated with disease severity: a systematic review 
and meta-analysis. Thorax. 2007; 62:944–949. [PubMed: 17526675]] which often occur in the 
exercising muscle of individuals with COPD [Larsen FJ, Schiffer TA, Borniquel S, Sahlin K, 
Ekblom B, Lundberg JO, Weitzberg E. Dietary inorganic nitrate improves mitochondrial 
efficiency in humans. Cell Metabolism. 2011; 13:149– 159. [PubMed: 21284982]]. 
It is well established that dietary nitrate consumption increases plasma nitrate and nitrite levels in 
COPD patients, as well as that dietary nitrate consumption increases submaximal exercise 
capacity in COPD patients. 
Dietary nitrate consumption also decreases resting systolic blood pressure in COPD patients. 
NO is a signalling molecule with multiple functions including regulation of vascular tone, 
mitochondrial respiration and skeletal muscle function [14. Gosker HR, Zeegers MP, Wouters 
EF, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is 
associated with disease severity: a systematic review and meta-analysis. Thorax. 2007; 62:944–
949. [PubMed: 17526675] 15. Hernandez A, Schiffer TA, Ivarsson N, Cheng AJ, Bruton JD, 
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Lundberg JO, Weitzberg E, Westerblad H. Dietary nitrate increases tetanic [Ca2+]i and 
contractile force in mouse fast-twitch muscle. The Journal of Physiology. 2012; 590:3575–3583. 
[PubMed: 22687611] 16. Ingram TE, Pinder AG, Bailey DM, Fraser AG, James PE. Low-dose 
sodium nitrite vasodilates hypoxic human pulmonary vasculature by a means that is not 
dependent on a simultaneous elevation in plasma nitrite. American Journal of Physiology Heart 
and Circulatory Physiology. 2010; 298:H331–339. [PubMed: 19940079]].  
NO is produced in two distinct ways in man. In many individuals with COPD, functional 
capacity is reduced to a level where activities of daily living may impose a challenge due to an 
energy requirement representing a high fraction of their maximal oxygen uptake. Whilst a 
number of cardiovascular and physiological benefits have been shown as a result of dietary 
nitrate supplementation in healthy populations, it tle is known about possible effects in clinical 
populations. 
 These abnormalities result in feelings of breathlessness and fatigue [Berry MJ, Rejeski WJ, 
Adair NE, Zaccaro D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. 
American Journal of Respiratory and Critical Care Medicine. 1999; 160:1248–1253. [PubMed: 
10508815]], with individuals often finding that activities of daily living are physically 
challenging. The beneficial effects of a diet rich in vegetables upon cardiovascular health [Berry 
MJ, Rejeski WJ, Miller ME, Adair NE, Lang W, Foy CG, Katula JA. A lifestyle activity 
intervention in patients with chronic obstructive pulmonary disease. Respiratory Medicine. 2010; 
104:829–839. [PubMed: 20347286]], risk of morbidity and mortality [Bescos R, Ferrer-Roca V, 
Galilea PA, Roig A, Drobnic F, Sureda A, Martorell M, Cordova A, Tur JA, Pons A. Sodium 
nitrate supplementation does not enhance performance of endurance athletes. Medicine and 
Science in Sports and Exercise. 2012; 44:2400–2409. [PubMed: 22811030]], and COPD 
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development [8. Borg GA. Psychophysical bases of perceived exertion. Medicine Science in 
Sports and Exercise. 1982; 14:377–381. 9. Breese BC, McNarry MA, Marwood S, Blackwell JR, 
Bailey SJ, Jones AM. Beetroot juice supplementation speeds O2 uptake kinetics and improves 
exercise tolerance during severe-intensity exercise initiated from an elevated metabolic rate. 
American Journal of Physiology Regulatory, Integrative and Comparative Physiology. 2013; 
305:R1441–1450.] have been well described. These positive effects have, in part, been attributed 
to inorganic nitrate which is found in particularly high quantities in leafy green vegetables and 
some root vegetables such as beetroot [Butler J, Chomsky DB, Wilson JR. Pulmonary 
hypertension and exercise intolerance in patients with heart failure. Journal of the American 
College of Cardiology. 1999; 34:1802–1806. [PubMed: 10577573] Berry]. Nitrate 
supplementation in the form of sodium nitrate or nitrate-rich beetroot juice has been shown to 
have remarkable effects in healthy young individuals and athletes, including reductions in the 
oxygen cost of exercise [Cermak NM, Res P, Stinkens R, Lundberg JO, Gibala MJ, van Loon LJ. 
No improvement in endurance performance after a single dose of beetroot juice. International 
Journal of Sport Nutrition and Exercise Metabolism. 2012; 22:470–478.], enhanced exercise 
tolerance/performance and reduced blood pressure (BP) [Cermak NM, Res P, Stinkens R, 
Lundberg JO, Gibala MJ, van Loon LJ. No improvement in endurance performance after a single 
dose of beetroot juice. International Journal of Sport Nutrition and Exercise Metabolism. 2012; 
22:470–478., Christensen PM, Nyberg M, Bangsbo J. Influence of nitrate supplementation on 
VO(2) kinetics and endurance of elite cyclists. Scandinavian Journal of Medicine & Science in 
Sports. 2013; 23:e21–31. [PubMed: 23020760]]. Assesed effects have subsequently been 
exercise and restored exercise tolerance and oxidative function to values observed in normoxia 
(Vanhatalo A, Fulford J, Bailey SJ, Blackwell JR, Winyard PG, Jones AM. Dietary nitrate 
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reduces muscle metabolic perturbation and improves exercise tolerance in hypoxia. The Journal 
of Physiology. 2011; 589:5517–5528. [PubMed: 21911616]). These results suggest that 
stimulating the NO3−→NO2−-→NO pathway via ingestion of dietary NO3− may have 
important therapeutic applications in improving muscle energetics and functional capacity during 
hypoxic conditions such as mild exercise in patients with cardiovascular, pulmonary and/or sleep 
disorders. 
Kelly et al. hypothesized that NO3− supplementation may also provide beneficial effects for 
older adults because of the age associated decline in NO signaling (Kelly J, Fulford J, Vanhatalo 
A, Blackwell JR, French O, Bailey SJ, Gilchrist M, Winyard PG, Jones AM. Effects of short-
term dietary nitrate supplementation on blood pressure, O2 uptake kinetics, and muscle and 
cognitive function in older adults. American Journal of Physiology Regulatory, Integrative and 
Comparative Physiology. 2013; 304:R73–83.). NO defect is a result of reduced availability of L-
arginine or the cofactor tetrahydrobiopterin, reduced endothelial NOS activity and/or increased 
superoxide production (Reckelhoff JF, Kellum JA, Blanchard EJ, Bacon EE, Wesley AJ, 
Kruckeberg WC. Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and 
nitrite, with aging. Life Sciences. 1994; 55:1895–1902. [PubMed: 7990649], Tiefenbacher CP. 
Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in the treatment of endothelial 
dysfunction? American Journal of Physiology Heart and Circulatory Physiology. 2001; 
280:H2484–2488. [PubMed: 11356602]). Kelly et al. reported that dietary supplementation of 
NO3− over a 2.5 day period significantly increased plasma NO2− levels and decreased resting 
blood pressure and the mean response time of VO2 in healthy older adults (Kelly J, Fulford J, 
Vanhatalo A, Blackwell JR, French O, Bailey SJ, Gilchrist M, Winyard PG, Jones AM. Effects 
of short-term dietary nitrate supplementation on blood pressure, O2 uptake kinetics, and muscle 
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and cognitive function in older adults. American Journal of Physiology Regulatory, Integrative 
and Comparative Physiology. 2013; 304:R73–83.). These results suggest that dietary NO3− 
intake has the potential to improve the exercise capacity and general health of older adults. 
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Figure 5. Illustation of the inflammatory cascade in response to cellular attack and possible 
pathways where betalains may exhibit inhibitory effects. PGF2, Prostaglandin F2; PGE2, 
Prostaglandin E2; COX1/2, Cyelooxygenase 1and 2; LOX, lipoxygenase; LOX-5, 5-
lipoxygenase; LOX-12, 12-lipoxygenase, HOCI, Hypochlorus acid; OH
-
, Hydroxyl radical; NF-
κΒ, Nuclear factor-Kappa B; AP-1, Activator protein1: IL-6, Interleukin-6; IL-8, Interleukin-8; 
IL-1β, Interleukin-1 beta; TNFa, tumor necrosis factor-alpha. 
 
 
Beetroot 
 
The well-documented health benefits of a diet high in fruit and vegetables has led to a growing 
interest in so-called “functional foods” and their application in health and disease. In recent 
years, the root vegetable Beta vulgaris rubra, otherwise known as red beetroot (herein referred to 
as beetroot) has attracted much attention as a health promoting functional food. Reports of its use 
as a natural medicine dates back to Roman times [Ninfali, P.; Angelino, D. Nutritional and 
functional potential of Beta vulgaris cicla and rubra. Fitoterapia 2013, 89, 188–199.]. Curently 
beetroot is agricultured in many countries worldwide, it is regularly consumed as part of the 
normal diet and is commonly used in manufacturing as a food colouring agent known as E162 
[2. Georgiev, V.G.; Weber, J.; Kneschke, E.M.; Denev, P.N.; Bley, T.; Pavlov, A.I. Antioxidant 
activity and phenolic content of betalain extracts from intact plants and hairy root cultures of the 
red beetroot Beta vulgaris cv. Detroit dark red. Plant Foods Hum. Nutr. 2010, 65, 105–111. 3. 
Zielińska-Przyjemska, M.; Olejnik, A.; Dobrowolska-Zachwieja, A.; Grajek, W. In vitro effects 
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of beetroot juice and chips on oxidative metabolism and apoptosis in neutrophils from obese 
individuals. Phytophera Res. 2009, 23, 49–55.]. Recent interest in beetroot has been primarily 
driven by the discovery that sources of dietary nitrate may have important implications for 
managing cardiovascular health [Lundberg, J.O.; Weitzberg, E.; Gladwin, M.T. The nitrate-
nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. 2008, 7, 156–167.]. 
However, beetroot is rich in several other bioactive compounds that may provide health benefits, 
particularly for disorders characterised by chronic inflammation. Consequently, the potential role 
for beetroot as an adjunct treatment in several clinical conditions that will be presented; 
Specifically, part of the aims of this review are: (1) to highlight evidence from recent studies 
showing the physiological and biological actions of beetroot; and (2) to evaluate its use as a 
nutritional intervention in health and disease, with a special emphasis on experimental studies 
relating to oxidative stress, inflammation, endothelial function and cognition. Recent studies 
have provided compelling evidence that beetroot ingestion offers beneficial physiological effects 
that may translate to improved clinical outcomes for several pathologies, such as hypertension, 
atherosclerosis, type 2 diabetes and dementia [1. Ninfali, P.; Angelino, D. Nutritional and 
functional potential of Beta vulgaris cicla and rubra. Fitoterapia 2013, 89, 188–199, 5–8 5. 
Gilchrist, M.; Winyard, P.G.; Fulford, J.; Anning, C.; Shore, A.C.; Benjamin, N. Dietary nitrate 
supplementation improves reaction time in type 2 diabetes: Development and application of a 
novel nitrate-depleted beetroot juice placebo. Nitric Oxide 2014, 40, 67–74. 6. Presley, T.D.; 
Morgan, A.R.; Bechtold, E.; Clodfelter, W.; Dove, R.W.; Jennings, J.M., Kraft, R.A.; King, 
R.A.; Laurienti, P.J.; Rejeskib, J.; et al. Acute effect of a high nitrate diet on brain perfusion in 
older adults. Nitric Oxide 2011, 24, 34–42. 7. Vanhatalo, A.; Bailey, S.J.; Blackwell, J.R.; di 
Menna, F.J.; Pavey, T.G.; Wilkerson, D.P.; Benjamin, N.; Winyard, P,G.; Jones, A.M. Acute and 
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chronic effects of dietary nitrate supplementation on blood pressure and the physiological 
responses to moderate-intensity and incremental exercise. Am. J. Physiol. -Reg. I 2010, 299, 
1121–1131. 8. Wootton-Beard, P.C.; Brandt, K.; Fell, D.; Warner, S.; Ryan, L. Effects of a 
beetroot juice with high neobetanin content on the early-phase insulin response in healthy 
volunteers. J. Nutr. Sci. 2011, 3, 1–9. ]. Hypertension in particular has been the target of many 
therapeutic interventions and there are numerous studies that show beetroot, delivered acutely as 
a juice supplement [9. Bailey, S.J.; Winyard, P.; Vanhatalo, A.; Blackwell, J.R.; Dimenna, F.J.; 
Wilkerson, D.P.; Tarr, J.; Benjamin, N.; Jones, A.M. Dietary nitrate supplementation reduces the 
O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans. J. 
Appl. Physiol. 2009, 107, 1144–1155. 10. Webb, A.J.; Patel, N.; Loukogeorgakis, S.; Okorie, 
M.; Aboud, Z.; Misra, S.; Rashid, R.; Miall, P.; Deanfield, J.; Benjamin, N.; et al. Acute blood 
pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion 
to nitrite. Hypertension 2008, 51, 784–790. 11. Jajja, A.; Sutyarjoko, A.; Lara, J.; Rennie, K.; 
Brandt, K.; Qadir, O.; Siervo, M. Beetroot supplementation lowers daily systolic blood pressure 
in older, overweight subjects. Nutr. Res. 2014, 34, 1–8.] or in bread [12. Hobbs, D.A.; Goulding, 
M.G.; Nguyen, A.; Malaver, T.; Walker, C.F., George, T.W.; Lovegrove, J.A. Acute ingestion of 
beetroot bread increases endothelium-independent vasodilation and lowers diastolic blood 
pressure in healthy men: A randomized controlled trial. J. Nutr. 2013, 143, 1399–1405. 13. 
Hobbs, D.A.; Kaffa, N.; George, T.W.; Methven, L.; Lovegrove, J.A. Blood pressure-lowering 
effects of beetroot juice and novel beetroot-enriched bread products in normotensive male 
subjects. Brit. J. Nutr. 2012, 108, 2066–2074.] significantly reduce systolic and diastolic blood 
pressure. Further discussion of beetroot’s anti-hypertensive potential is summarised in several 
reviews: [14. Hobbs, D.A.; George, T.W.; Lovegrove, J.A. The effects of dietary nitrate on blood 
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pressure and endothelial function: A review of human intervention studies. Nutr. Res. Rev. 2013, 
26, 210–222. 15. Kapil, V.; Weitzberg, E.; Lundberg, J.O.; Ahluwalia, A. Clinical evidence 
demonstrating the utility of inorganic nitrate in cardiovascular health. Nitric Oxide 2014, 38, 45–
57. 16. Lidder, S.; Webb, A.J. Vascular effects of dietary nitrate (as found in green leafy 
vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway. Br. J. Clin. Pharmacol. 2013, 
75, 677–696.]. Beetroot’s effect on the vasculature is largely attributed to its high inorganic 
nitrate content (250 mg∙kg−1 of fresh weight; [Ormsbee, M.J.; Lox, J.; Arciero, P.J. Beetroot 
juice and exercise performance. J. Int. Soc. Sports Nutr. 2013, 5, 27–35.]). Nitrate itself is not 
considered to mediate any specific physiological function; rather, nitrates beneficial effects are 
attributed to its in vivo reduction to nitric oxide (NO), a multifarious messenger molecule with 
important vascular and metabolic functions [14. Hobbs, D.A.; George, T.W.; Lovegrove, J.A. 
The effects of dietary nitrate on blood pressure and endothelial function: A review of human 
intervention studies. Nutr. Res. Rev. 2013, 26, 210–222. 15. Kapil, V.; Weitzberg, E.; Lundberg, 
J.O.; Ahluwalia, A. Clinical evidence demonstrating the utility of inorganic nitrate in 
cardiovascular health. Nitric Oxide 2014, 38, 45–57. 16. Lidder, S.; Webb, A.J. Vascular effects 
of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric 
oxide pathway. Br. J. Clin. Pharmacol. 2013, 75, 677–696. Ormsbee, M.J.; Lox, J.; Arciero, P.J. 
Beetroot juice and exercise performance. J. Int. Soc. Sports Nutr. 2013, 5, 27–35. 18. Machha, 
A.; Schechter, A.N. Dietary nitrite and nitrate: A review of potential mechanisms of 
cardiovascular benefits. Eur. J. Nutr. 2011, 50, 293–303.]. The generation of NO via nitrate 
involves a series of sequential steps that have been well described in the literature [4. Lundberg, 
J.O.; Weitzberg, E.; Gladwin, M.T. The nitrate-nitrite-nitric oxide pathway in physiology and 
therapeutics. Nat. Rev. 2008, 7, 156–167., 19. Lundberg, J.O.; Carlström, M.; Larsen, F.J.; 
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Weitzberg, E. Roles of dietary inorganic nitrate in cardiovascular health and disease. Cardiovas 
Res. 2011, 89, 525–532]. Briefly, ingested nitrate is first absorbed through the upper part of the 
small intestine into the systemic circulation [4. Lundberg, J.O.; Weitzberg, E.; Gladwin, M.T. 
The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. 2008, 7, 156–
167.,, 15. Kapil, V.; Weitzberg, E.; Lundberg, J.O.; Ahluwalia, A. Clinical evidence 
demonstrating the utility of inorganic nitrate in cardiovascular health. Nitric Oxide 2014, 38, 45–
57.]. It is then estimated that 25% of the circulating nitrate enters the entero-salivary cycle where 
bacterial species located at the posterior aspect of the tongue bioactivate or reduce salivary 
nitrate to nitrite [16. Lidder, S.; Webb, A.J. Vascular effects of dietary nitrate (as found in green 
leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway. Br. J. Clin. Pharmacol. 
2013, 75, 677–696., Lundberg, J.O.; Carlström, M.; Larsen, F.J.; Weitzberg, E. Roles of dietary 
inorganic nitrate in cardiovascular health and disease. Cardiovas Res. 2011, 89, 525–532.]. 
Because salivary bacteria facilitate the reduction reaction that converts nitrate to nitrite, spitting 
out saliva or taking oral anti-bacterial treatments, like dental mouthwash for example, has been 
shown to diminish nitrate-nitrite conversion [Webb, A.J.; Patel, N.; Loukogeorgakis, S.; Okorie, 
M.; Aboud, Z.; Misra, S.; Rashid, R.; Miall, P.; Deanfield, J.; Benjamin, N.; et al. Acute blood 
pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion 
to nitrite. Hypertension 2008, 51, 784–790.,18 Machha, A.; Schechter, A.N. Dietary nitrite and 
nitrate: A review of potential mechanisms of cardiovascular benefits. Eur. J. Nutr. 2011, 50, 
293–303.]. Under normal circumstances, however, salivary nitrite is re-absorbed into the 
circulation via the stomach where it is metabolised to NO and other nitrogen oxides by a variety 
of reductase enzymes [Lundberg, J.O.; Weitzberg, E.; Gladwin, M.T. The nitrate-nitrite-nitric 
oxide pathway in physiology and therapeutics. Nat. Rev. 2008, 7, 156–167.,10. Webb, A.J.; 
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Patel, N.; Loukogeorgakis, S.; Okorie, M.; Aboud, Z.; Misra, S.; Rashid, R.; Miall, P.; Deanfield, 
J.; Benjamin, N.; et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties 
of dietary nitrate via bioconversion to nitrite. Hypertension 2008, 51, 784–790., 13. Hobbs, D.A.; 
Kaffa, N.; George, T.W.; Methven, L.; Lovegrove, J.A. Blood pressure-lowering effects of 
beetroot juice and novel beetroot-enriched bread products in normotensive male subjects. Brit. J. 
Nutr. 2012, 108, 2066–2074.]. However, as previously mentioned, nitrate is not the only 
constituent of beetroot proposed to have beneficial effects in health and disease. Beetroot is a 
rich source of phytochemical compounds (Figure 1), that includes ascorbic acid, carotenoids, 
phenolic acids and flavonoids [Georgiev, V.G.; Weber, J.; Kneschke, E.M.; Denev, P.N.; Bley, 
T.; Pavlov, A.I. Antioxidant activity and phenolic content of betalain extracts from intact plants 
and hairy root cultures of the red beetroot Beta vulgaris cv. Detroit dark red. Plant Foods Hum. 
Nutr. 2010, 65, 105–111., 20. Kujala, T.S.; Vienola, M.S.; Klika, K.D.; Loponen, J.M.; Pihlaja, 
K. Betalain and phenolic compositions of four beetroot (Beta vulgaris) cultivars. Eur. Food. Res. 
Technol. 2002, 214, 505–510. 21. Wootton-Beard, P.C.; Ryan, L. A beetroot juice shot is a 
significant and convenient source of bioaccessible antioxidants. J. Funct. Foods 2011, 3, 329–3  
34.]. 
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Figure 6. Overview of potentially bioactive compounds in beetroot (based on data from [1. 
Ninfali, P.; Angelino, D. Nutritional and functional potential of Beta vulgaris cicla and rubra. 
Fitoterapia 2013, 89, 188–199. 2. Georgiev, V.G.; Weber, J.; Kneschke, E.M.; Denev, P.N.; 
Bley, T.; Pavlov, A.I. Antioxidant activity and phenolic content of betalain extracts from intact 
plants and hairy root cultures of the red beetroot Beta vulgaris cv. Detroit dark red. Plant Foods 
Hum. Nutr. 2010, 65, 105–111. 20. Kujala, T.S.; Vienola, M.S.; Klika, K.D.; Loponen, J.M.; 
Pihlaja, K. Betalain and phenolic compositions of four beetroot (Beta vulgaris) cultivars. Eur. 
Food. Res. Technol. 2002, 214, 505–510.]).  
 
Beetroot is also one of the few vegetables that contain a group of highly bioactive pigments 
known as betalains [22. Lee, C.H.; Wettasinghe, M.; Bolling, B.W.; Ji, L.L.; Parkin, K.L. 
Betalains, phase II enzyme-inducing components from red beetroot (Beta vulgaris L.) extracts. 
Nutr. Cancer 2005, 53, 91–103, 23. Vulić, J.J.; Ćebović, T.N.; Čanadanović-Brunet, J.M.; 
Ćetković, G.S.; Čanadanović, V.M.;  Djilas, S.M.; Tumbas Šaponjac, V.T. In vivo and in vitro 
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antioxidant effects of beetroot pomace extracts. J. Funct. Foods 2014, 6, 168–175.]. Members of 
the betalain family are categorised as betacyanin pigments that are red-violet in colour or 
betaxanthin pigments that are yellow-orange in colour [1. Ninfali, P.; Angelino, D. Nutritional 
and functional potential of Beta vulgaris cicla and rubra. Fitoterapia 2013, 89, 188–199.]. 
Betalains have reported to have high antioxidant and anti-inflammatory capabilities in vitro and a 
variety of in vivo animal models [3. Zielińska-Przyjemska, M.; Olejnik, A.; Dobrowolska-
Zachwieja, A.; Grajek, W. In vitro effects of beetroot juice and chips on oxidative metabolism 
and apoptosis in neutrophils from obese individuals. Phytophera Res. 2009, 23, 49–55., 23. 
Vulić, J.J.; Ćebović, T.N.; Čanadanović-Brunet, J.M.; Ćetković, G.S.; Čanadanović, V.M.;  
Djilas, S.M.; Tumbas Šaponjac, V.T. In vivo and in vitro antioxidant effects of beetroot pomace 
extracts. J. Funct. Foods 2014, 6, 168–175. 24. Pavlov, A.; Georgiev, V.; Ilieva, M. Betalain 
biosynthesis by red beet (Beta vulgaris L.) hairy root culture. Process. Biochem. 2005, 40, 1531–
1533. 25. Tesoriere, L.; Allegra, M.; Butera, D.; Livrea, M.A. Absorption, excretion, and 
distribution of dietary antioxidant betalains in LDLs: Potential health effects of betalains in 
humans. Am. J. Clin. Nutr. 2004, 80, 941–945. 26. Vidal, P.J.; López-Nicolás, J.M.; Gandía-
Herrero, F.; García-Carmona, F. Inactivation of lipoxygenase and cyclooxygenase by natural 
betalains and semi-synthetic analogues. Food. Chem. 2014, 154, 246–254.]. This has emerged 
interest in a possible role for beetroot in clinical pathologies characterised by oxidative stress and 
chronic inflammation such as liver disease [1. Ninfali, P.; Angelino, D. Nutritional and 
functional potential of Beta vulgaris cicla and rubra. Fitoterapia 2013, 89, 188–199, Vulić, J.J.; 
Ćebović, T.N.; Čanadanović-Brunet, J.M.; Ćetković, G.S.; Čanadanović, V.M.;  Djilas, S.M.; 
Tumbas Šaponjac, V.T. In vivo and in vitro antioxidant effects of beetroot pomace extracts. J. 
Funct. Foods 2014, 6, 168–175], arthritis [27. Pietrzkowski, Z.; Nemzer, B.; Spórna, A.; Stalica, 
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P.; Tresher, W.; Keller, R.; Jiminez, R.; Michalowski, T.; Wybraniec, S. Influence of betalin-rich 
extracts on reduction of discomfort associated with osteoarthritis. New. Med. 2010, 1, 12–17.] 
and even cancer [28. Das, S.; Williams, D.S.; Das, A.; Kukreja, R.C. Beet root juice promotes 
apoptosis in oncogenic MDA-MB-231 cells while protecting cardiomyocytes under doxorubicin 
treatment. J. Exp. Second. Sci. 2013, 2, 1–6. 29. Kapadia, G.J.; Azuine, M.A.; Rao, G.S.; Arai, 
T.; Iida, A.; Tokuda, H. Cytotoxic effect of the red beetroot (Beta vulgaris L.) extract compared 
to doxorubicin (Adriamycin) in the human prostate (PC-3) and breast (MCF-7) cancer cell lines. 
Anti -Cancer Agent Med. Chem. 2011, 11, 280–284. 30. Kapadia, G.J.; Azuine, M.A.; Sridhar, 
R.; Okuda, Y.; Tsuruta, A.; Ichiishi, E.; Mukainakec, T.; Takasakid, M.; Konoshimad, T.; 
Nishinoc, H.; et al. Chemoprevention of DMBA-induced UV-B promoted, NOR-1-induced TPA 
promoted skin carcinogenesis, and DEN-induced phenobarbital promoted liver tumors in mice 
by extract of beetroot. Pharmacol. Res. 2003, 47, 141–148.  31. Kapadia, G.J.; Rao, G.S.; 
Ramachandran, C.; Iida, A.; Suzuki, N.; Tokuda, H. Synergistic cytotoxicity of red beetroot 
(Beta vulgaris L.) extract with doxorubicin in human pancreatic, breast and prostate cancer cell 
lines. J. Complement. Med. 2013, 10, 113–122.]. 
 
Knowing all these benefits of dietary nitrate on cardiovascular function and more, we decided to 
investigate the effect of this juice in patients with RA and COPD. 
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  2.4. CHRONIC INFLAMMATION AND OXIDATIVE STRESS 
Chronic inflammation is a pathological condition characterized by continued active inflammation 
response and tissue destruction. Many of the immune cells including macrophages, neutrophils 
and eosinophils are involved directly or by production of inflammatory cytokine production in 
pathology of chronic inflammation. From literatures, it appeares that there is a general concept 
that chronic inflammation can be a major cause of cancers and express aging processes. 
Moreover, many studies suggest that chronic inflammation could have serious role in wide 
variety of age-related diseases including diabetes, cardiovascular and autoimmune diseases. 
Inflammatory process induces oxidative stress and reduces cellular antioxidant capacity. 
Overproduced free radicals react with cell membrane fatty acids and proteins impairing their 
function permanently. In addition, free radicals can lead to mutation and DNA damage that can 
be a predisposing factor for cancer and age-related disorders. (Recent Pat Inflamm Allergy Drug 
Discov. 2009 Jan;3(1):73-80. 
 
2.4. ENDOTHELIAL FUNCTION, CHRONIC INFLAMMATION AND OXIDATIVE 
STRESS 
Chronic obstructive pulmonary disease (COPD) is associated with increased cardiovascular 
mortality. Endothelial dysfunction supports this association. In cross-sectional study the impact 
of airflow obstruction, systemic inflammation, oxidative stress, sympathetic activation, 
hypoxaemia and physical activity on endothelial function in COPD was determined. The 
findings of this study demonstrate that the severity of airflow obstruction is a significant 
determinant of endothelial function in patients with COPD and that the level of physical activity 
seems to have a favourable effect on this association. Determinants of endothelial function in 
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patients with COPD Christian F. Clarenbach1, Oliver Senn2, Noriane A. Sievi1, Giovanni 
Camen1, Arnoldus J.R. van Gestel1, Valentina A. Rossi1, Milo A. Puhan3, Robert Thurnheer4, 
Erich W. Russi1,5 and Malcolm Kohler1, 
Moreover, chronic inflammation is a pathological condition characterized by continued active 
inflammation response and tissue destruction. The majority of the immune cells including 
macrophages, neutrophils and eosinophils are involved directly or by production of inflammatory 
cytokine production in pathology of chronic inflammation. From literatures, it appeares that there 
is a general concept that chronic inflammation can be a major cause of cancers and express aging 
processes. Nevertheless, many studies suggest that chronic inflammation could have serious role 
in wide variety of age-related diseases including diabetes, cardiovascular and autoimmune 
diseases. Inflammatory process induces oxidative stress and reduces cellular antioxidant 
capacity. The overproduced free radicals react with cell membrane fatty acids and proteins 
impairing their function permanently. In addition, free radicals can lead to mutation and DNA 
damage that can be a predisposing factor for cancer and age-related disorders. (Recent Pat 
Inflamm Allergy Drug Discov. 2009 Jan;3(1):73-80. Chronic inflammation and oxidative stress 
as a major cause of age-related diseases and cancer. Khansari N1, Shakiba Y, Mahmoudi M.) 
Oxidative stress is essentially an imbalance between the production of free radicals and the 
ability of the body to counteract or detoxify their harmful effects through neutralization by 
antioxidants. 
Oxidative stress is well known to be involved in the pathogenesis of lifestyle-related diseases, 
including atherosclerosis, hypertension, diabetes mellitus, ischemic diseases, and malignancies. 
Oxidative stress has been defined as harmful because oxygen free radicals attack biological 
molecules such as lipids, proteins, and DNA.  However, oxidative stress also has a useful role in 
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physiologic adaptation and in the regulation of intracellular signal transduction. Therefore, a 
more useful definition of oxidative stress may be “a state where oxidative forces exceed the 
antioxidant systems due to loss of the balance between them.” 
(What Is Oxidative Stress? JMAJ 45(7): 271–276, 2002 Toshikazu YOSHIKAWA* and Yuji 
NAITO** Professor* and Associate Professor**, First Department of Medicine, Kyoto 
Prefectural University of Medicine) 
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3. METHODOLOGY 
Taken into consideration all the aforementioned possible benefits of dietary nitrate on 
cardiovascular function and other health aspects, we decided to investigate the effects of BJ, 
which is rich in nitrates, in chronic patients that are susceptible to CVD. 
The purpose of the present study was to investigate the effects of beetroot juice (BJ) 
consumption for 2 weeks on the severity of disease, endothelial function and biochemical indices 
in RA and COPD patients. 
 
3.1. PARTICIPANTS 
Eighteen patients, 9 with COPD (6 men, 3 women; age: 60.9 ± 12.6; BMI: 26.0 ± 2.1) and 9 with 
RA (2 men, 7 women; age: 54.3 ± 11.7; BMI: 26.9 ± 3.6), and 8 healthy controls (3 men, 5 
women; age: 55.7 ± 6.8; BMI: 27.8 ± 3.2; control group - CG) participated in the study. RA 
patients met the diagnostic criteria of RA (Arnett et al., 1988). COPD patients were of all stages 
of disease as defined by the GOLD 2011 (Han et al., 2013). 
 
Inclusion/exclusion criteria 
RA: PA patients with a diagnosis of RA according to the criteria of the American company 
rheumatology for less than 5 years, stable status of disease for four weeks before the study, 
constant medication for four weeks before the study, without known CVD or hypertension. 
COPD: COPD patients with stabilized disease status for four weeks without response to 
bronchodilator, full capacity cooperation in spirometry, COPD of any stage if the patient is able 
to walk, patients not receiving oxygen therapy at house. 
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CG: Non-smoking individuals with non-declared pathology that do not receive medication, 
exercising less than 3 times per week. 
 
3.2. EXPERIMENTAL DESIGN 
Participants were screened by their doctor and were informed about the study protocol, the 
associated risks and benefits and they signed an informed consent form. The procedures of the 
study were in accordance with the 1975 Declaration of Helsinki. Ethics approval was received 
from the University of Thessaly review board. 
Participants were randomly assigned to either the experimental (beetroot juice - BJ) or the 
control leg (blackcurrant juice; control juice - CJ). They were then asked to report at the testing 
venue (Ultrasonography Laboratory, General Hospital of Trikala) early in the morning, 
following an overnight fast. Demographic and disease characteristics were recorded and 
somatometric characteristics (i.e. height, weight and waist/hip) were assessed. Endothelial 
function the ability to exercise and other physiological parameters were also measured. 
Moreover, a blood sample was obtained in order to later determined indices of redox status and 
complete blood count. Participants consumed 70ml of BJ daily for two weeks. After that, they 
reported to the testing venue where they were re-evaluated. They crossed over to the other leg of 
the study after a two-week washout period. A 2-day diet recall was also obtained at the first 
evaluation, and then participants were adviced to follow the same diet for 2 days before each 
next evaluation. 
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3.3. BLOOD COLLECTION AND HANDLING 
Blood samples were drawn from a forearm vein. A small portion of blood was collected into 
ethylenediamine tetra acetic acid (EDTA) tubes and shaken thoroughly for the determination of 
complete blood count (CBC). For plasma preparation, a portion of blood was collected in 
vacutainer tubes containing EDTA and shaken thoroughly. Plasma was separated by 
centrifugation at 1370 x g for 10 min at 4
o
C. The supernatant was transferred into Eppendorf 
tubes® and was immediately stored at 80oC for later determination of total antioxidant capacity 
(TAC). For red blood cell lysate preparation, packed erythrocytes were diluted with distilled 
water (1:1 v/v), vortexed vigorously, and centrifuged at 4000 x g for 15 min at 4
o
C. The 
supernatant was transferred into Eppendorf tubes® and stored at -80oC for later determination of 
catalase activity. For serum separation, another portion of blood was collected in tubes 
containing clot activator, left at room temperature for 20 min to clot, and centrifuged at 1370 x g 
for 10 min at 4
oC. The supernatant was transferred into Eppendorf tubes® and was immediately 
stored at 80
o
C for later determination of uric acid (UA) and bilirubin. 
 
3.4. METHODS 
 
Anthropometric and physiological measurements 
Body weight was measured to the nearest 0.1 kg (Tanita Body Fat Monitor/Scale TBF-521; 
Tanita, Inc., IL, USA), with participants lightly dressed and barefoot; standing height was 
measured to the nearest 0.1 cm (Stadiometer 208; Seca, Birmingham, UK). Blood pressure (BP) 
was measured with a manual sphygmomanometer (FC-101 Aneroid Sphygmomanometer; Focal 
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Corporation, Japan). The ability to exercise using the 6-min walk test (Balke, 1963) was also 
evaluated. 
 
Endothelial function 
Endothelial function was estimated using the technique of flow-mediated vasodilatation, which 
assesses the diameter of the lumen of the bracial artery pre and post a 5-minute occlusion to the 
blood flow of the forearm. According to Corretti et al. (2002), endothelial function was 
examined by high-resolution ultrasound in the brachial artery after blocking blood flow in the 
forearm for 5 minutes. The diameter of the artery before blocking (reference diameter) was 
compared to the maximum diameter of the artery after the restoration of blood flow, and the 
vasodilation rate was estimated. 
 
Severity of disease 
MRC Dyspnoea Scale (Fletcher et al., 1959) and COPD Assessment Test (COPD Assessment 
Test website, 2017) were used for COPD patients. DAS-28 (DAS-score website, 2017) and the 
Health assessment questionnaire (HAQ-DI) (Fries et al., 1980) for RA patients. 
 
Blood samples analyses 
Assays were performed in duplicate. 
Assays in whole blood: CBC [white blood cell (WBC), lymphocytes (LYM), monocytes (MON), 
granulocytes (GRA), lymphocyte percentage (LYM%), monocyte percentage (MON%), 
granulocyte percentage (GRA%), red blood cell count (RBCc), hemoglobin (HGB), hematocrit 
(Hct), mean cell volume (MCV), mean cell hemoglobin (MCH), mean cell hemoglobin 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:03:26 EEST - 137.108.70.13
Σ ε λ ί δ α  | 96 
 
96 
 
concentration (MCHC), red blood cell distribution width (RDW), platelets (PLT), mean platelet 
volume (MPV), platelecrit (PCT), platelet distribution width (PDW)] was measured with a 
Mythic 18 (Orphee S.A., Geneva, Switzerland) autoanalyser.  
Assays in plasma: TAC was determined by a method based on the scavenging of 1,1-diphenyl-2-
picrylhydrazyl, according to Janaszewska and Bartosz (2002). 
Assays in serum: UA and bilirubin were measured in a Clinical Chemistry Analyzer Z 1145 
(Zafiropoulos Diagnostica, Athens, Greece) with commercially available kits (Zafiropoulos, 
Athens, Greece). 
Assays in red blood cell lysate: Catalase activity was determined according to a method by Aebi 
(1984). 
 
Test juice 
The BJ used in this study was Beet It Sport shots (James White Drinks Ltd, U.K.), which is a 
100% natural source of nitrate. It constitutes of concentrated beetroot juice 
(98%) and lemon juice (2%). It contains at least 400 mg of natural nitrate, and 
no preservatives, additives or artificial flavours. It is suitable for vegetarians and 
vegans, and it is GMO free, gluten and dairy free. 
Ingredients. Concentrated beetroot juice (98%), lemon juice (2%); made from 
concentrates. 
 
Table 1. Nutritional info of the test juice (per 100g). 
Energy 414kJ / 97kcal 
Fat 0.2g 
   of which saturates <0.1g 
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Carbohydrates 20g 
   of which sugars 13g 
Protein 4g 
Salt 0.3g 
 
Control juice 
The control juice (CJ) was a product of blackcurrant juice (Ribena, Lucozade 
Ribena Suntory Ltd, U.K.) 
Ingredients. Water, Sugar, Blackcurrant Juice from Concentrate (23%), Acid (Citric Acid), 
Vitamin C, Preservatives (Potassium Sorbate, Sodium Bisulphite), Colour (Anthocyanins). 
 
Table 2. Nutritional info of the control juice (per 100g). 
Energy 181kJ / 43kcal 
Fat 0g 
   of which saturates 0g 
Carbohydrates 10.5g 
   of which sugars 10.5g 
Protein 0g 
Salt 0g 
 
 
3.5. STATISTICAL ANALYSIS 
Two-way repeated measures ANOVA was performed to analyze the data. Moreover, pairwise 
comparisons were performed through simple contrasts and simple main effects analysis using the 
Bonferroni test method. 
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The level of statistical significance was set at p<0.05. The statistical programme used was SPSS 
version 15.0 (SPSS Inc., USA).  
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4. RESULTS 
 
Antropometric and physiological characteristics 
 
Table 3. Antropometric and physiological characteristics of COPD patients following BJ and CJ 
consumption (Mean ± SD). 
Index Pre BJ Post BJ Pre CJ Post CJ 
BMI (kg/m^2) 26.0 ± 2.1 26.1 ± 2.1 26.9 ± 2.1 26.3 ± 2.2 
Waist (cm) 94.0 ± 6.8 93.9 ± 6.7 94.1 ± 6.6 94.8 ± 6.1 
Hip (cm) 92.4 ± 5.8 92.0 ± 5.7 92.9 ± 5.9 93.7 ± 5.6 
WHR 1.078 ± 0.17 1.081 ± 0.17 1.076 ± 0.17 1.076 ± 0.17 
Resting Heart Rate 79.5 ± 4.5 80.8 ± 4.4 76.8 ± 3.4 83.7 ± 3.3# 
Systolic Blood Pressure 131.4 ± 13.4 128.3 ± 13.8 127.3 ± 12.2 126.3 ± 12.2 
Diastolic Blood Pressure 83.1 ± 3.5 77.4 ± 4.1 79.7 ± 2.9 78 ± 2.9 
6-min Walk Test (m) 379.2 ± 30.3 432.3 ± 39.5 418.9 ± 37.1 382.3 ± 26.1 
#
Significant difference (p<0.05) from BJ consumption at the same time point. 
 
Table 4. Antropometric and physiological characteristics of RA patients following BJ and CJ 
consumption (Mean ± SD). 
Index Pre BJ Post BJ Pre CJ Post CJ 
BMI (kg/m^2) 26.9 ± 3.6 27.1 ± 3.8 27.2 ± 3.8 27.4 ± 3.7 
Waist (cm) 89.3 ± 4.8 88.8 ± 5.3 89.1 ± 5.3 89.3 ± 5.2 
Hip (cm) 85.0 ± 7.2 83.0 ± 7.1 83.0 ± 7.1 83.5 ± 7.3 
WHR 1.138 ± 0.14 1.162 ± 0.15 1.172 ± 0.16 1.172 ± 0.16 
Resting Heart Rate 69.0 ± 4.1 80.5 ± 4.4 71.5 ± 2.3 76.5 ± 3.4 
Systolic Blood Pressure 122.9 ± 3.3 116.8 ± 2.5 117.2 ± 3.7# 119.7 ± 3.9 
Diastolic Blood Pressure 77.1 ± 2.5 73.2 ± 1.6 73.0 ± 2.1# 74.0 ± 2.0 
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6-min Walk Test (m) 456.6 ± 29.8 456.1 ± 26.5 460.0 ± 24.1 458.6 ± 26.1 
#
Significant difference (p<0.05) from BJ consumption at the same time point. 
 
Table 5. Antropometric and physiological characteristics of the control group following BJ and 
CJ consumption (Mean ± SD). 
Index Pre BJ Post BJ Pre CJ Post CJ 
BMI (kg/m^2) 27.8 ± 1.1 27.8 ± 1.2 27.6 ± 1.2 27.6 ± 1.1 
Waist (cm) 96.0 ± 4.8 95.0 ± 4.8 93.8 ± 5.1 92.7 ± 4.8# 
Hip (cm) 89.7 ± 7.7 89.5 ± 7.6 88.3 ± 7.2 89.4 ± 7.5 
WHR 1.149 ± 0.15 1.143 ± 0.15 1.139 ± 0.14 1.115 ± 0.14* 
Resting Heart Rate 78.8 ± 6.3 74.6 ± 4.9 71.4 ± 4.9 77.8 ± 4.8* 
Systolic Blood Pressure 115.8 ± 8.6 112.0 ± 6.6 100.8 ± 8.8 113.6 ± 9.3 
Diastolic Blood Pressure 66.0 ± 2.4 65.2 ± 2.2 62.0 ± 3.7 66.8 ± 6.7 
6-min Walk Test (m) 486.3 ± 24.1 530.9 ± 19.7 527.1 ± 21.3# 486.3 ± 42.9 
*Significant difference (p<0.05) from pre-intervention at the same condition. 
#
Significant difference (p<0.05) from BJ consumption at the same time point. 
 
Endothelial function 
No difference in pre-occlusion diameter between any of the time-points was observed. 
Endothelial function significantly improved following BJ consumption in both experimental 
groups (RA: pre: 2.6% [0.9 – 6.2], post: 10.7% [6.2 – 11.7]; p=0.013) (COPD: pre: 3.4% [1.2 – 
4.8], post: 7.8% [3.6 – 10.2]; p=0.034). However, endothelial function remained relatively 
unaffected by the consumption of the control juice (Overall: pre: 3.9% [0 – 5.1], post: 4.2% [2.3 
– 6.1]; p=0.26). 
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Complete blood count 
 
Table 6. Complete blood count indices after PJ and CJ consumption in COPD patients. 
Index Pre BJ Post BJ Pre CJ Post CJ Normal rage 
WBC (10
3/μl) 6.82 ± 0.7 8.68 ± 1.9 6.60 ± 0.7 8.68 ± 2.4 4.0-12.0 
LYM (10
3/μl) 1.88 ± 0.3 2.20 ± 0.3 2.20 ± 0.3 2.14 ± 0.4 1.0-5.0 
MON (10
3/μl) 0.52 ± 0.08 0.62 ± 0.14 0.44 ± 0.06 0.58 ± 0.16 0.1-1.0 
GRA (10
3/μl) 4.42 ± 0.7 5.90 ± 1.8 3.94 ± 0.4 5.94 ± 2.3 2.0-8.0 
LYM % 28.5 ± 5.0 29.1 ± 6.3 33.1 ± 2.0 29.8 ± 5.6 25.0-50.0 
MON % 7.46 ± 0.7 6.78 ± 0.4 6.82 ± 0.8 6.82 ± 0.6 2.0-10.0 
GRA % 64.0 ± 5.2 64.1 ± 6.2 60.0 ± 2.4 63.4 ± 5.8 50.0-80.0 
RBCc 
(10
6/μl) 
4.96 ± 0.3 5.10 ± 0.3 4.77 ± 0.3 4.88 ± 0.2 4.00-6.20 
HGB (g/dl) 13.3 ± 0.3 13.5 ± 0.2 12.3 ± 0.5# 12.8 ± 0.2# 11.0-18.0 
HCT % 44.2 ± 0.7 45.0 ± 0.5 41.6 ± 1.3# 43.6 ± 0.3 35.0-55.0 
MCV (μm3) 90.3 ± 4.6 89.1 ± 4.1 88.2 ± 4.1 89.6 ± 4.7 80.0-100.0 
MCH (pg) 27.1 ± 1.3 26.8 ± 1.4 26.0 ± 1.1 26.5 ± 1.3 26.0-34.0 
MCHC (g/dl) 30.1 ± 0.3 30.0 ± 0.4 29.5 ± 0.5 29.6 ± 0.2 31.0-35.5 
RDW % 14.1 ± 0.5 13.7 ± 0.4 14.0 ± 0.6 14.2 ± 0.5 10.0-16.0 
PLT (10
3/μl) 264.3 ± 25.5 256.8 ± 27.1 247.3 ± 16.2 253.0 ± 10.9 150-400 
MPV (μm3) 7.88 ± 0.3 7.96 ± 0.4 8.02 ± 0.3 7.88 ± 0.4 7.0-11.0 
PCT % 0.208 ± 0.02 0.204 ± 0.01 0.196 ± 0.01 0.200 ± 0.01 0.200-0.500 
PDW % 14.6 ± 0.7 14.3 ± 1.0 14.4 ± 1.2 14.7 ± 0.4 10.0-18.0 
ESR (mm/h) 32.5 ± 13.5 31.0 ± 12.9 31.8 ± 14.1 33.0 ± 10.4 <20 
#
Significant difference (p<0.05) from BJ consumption at the same time point. 
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Table 7. Complete blood count indices after PJ and CJ consumption in RA patients. 
Index Pre BJ Post BJ Pre CJ Post CJ Normal rage 
WBC (10
3/μl) 5.89 ± 0.3 6.66 ± 0.7 5.80 ± 0.4 6.34 ± 0.5 4.0-12.0 
LYM (10
3/μl) 1.88 ± 0.22 2.14 ± 0.16 2.01 ± 0.14 2.00 ± 0.18 1.0-5.0 
MON (10
3/μl) 0.44 ± 0.06 0.44 ± 0.05 0.44 ± 0.05 0.43 ± 0.04 0.1-1.0 
GRA (10
3/μl) 3.56 ± 0.2 4.09 ± 0.6 3.36 ± 0.3 3.93 ± 0.5 2.0-8.0 
LYM % 31.66 ± 2.7 33.04 ± 2.3 35.07 ± 1.8 32.13 ± 3.1 25.0-50.0 
MON % 7.37 ± 0.9 6.69 ± 0.8 7.36 ± 0.7 7.00 ± 0.9 2.0-10.0 
GRA % 60.96 ± 3.3 60.11 ± 3.1 57.57 ± 2.1 60.87 ± 3.8 50.0-80.0 
RBCc 
(10
6/μl) 
4.62 ± 0.31 4.50 ± 0.32 4.56 ± 0.30 4.42 ± 0.29 4.00-6.20 
HGB (g/dl) 12.4 ± 0.7 12.0 ± 0.6 11.9 ± 0.7 11.6 ± 0.4 11.0-18.0 
HCT % 39.2 ± 2.1 37.8 ± 1.8* 38.2 ± 2.1 37.2 ± 1.4 35.0-55.0 
MCV (μm3) 86.1 ± 4.9 85.9 ± 5.9 85.06 ± 5.1 85.8 ± 5.2 80.0-100.0 
MCH (pg) 27.2 ± 2.0 27.3 ± 2.1 26.6 ± 1.8 26.7 ± 1.8 26.0-34.0 
MCHC (g/dl) 31.6 ± 1.0 31.8 ± 1.0 31.2 ± 0.7 31.1 ± 0.5 31.0-35.5 
RDW % 14.8 ± 0.6 14.5 ± 0.5 14.5 ± 0.5 15.0 ± 0.6
#
 10.0-16.0 
PLT (10
3/μl) 218.2 ± 11.7 230.0 ± 12.9 235.3 ± 9.4 227.3 ± 7.4 150-400 
MPV (μm3) 8.20 ± 0.1 8.40 ± 0.3 8.53 ± 0.1
#
 8.32 ± 0.2 7.0-11.0 
PCT % 0.177 ± 0.01 0.193 ± 0.01 0.201 ± 0.01 0.188 ± 0.01 0.200-0.500 
PDW % 14.97 ± 0.6 15.10 ± 0.5 14.02 ± 0.3 14.62 ± 0.6 10.0-18.0 
ESR (mm/h) 30.38 ± 9.6 30.63 ± 10.0 41.50 ± 11.4 36.5 ± 11.2 <20 
*Significant difference (p<0.05) from pre-intervention at the same condition. 
#
Significant difference (p<0.05) from BJ consumption at the same time point. 
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Table 8. Complete blood count indices after PJ and CJ consumption in control group. 
Index Pre BJ Post BJ Pre CJ Post CJ Normal rage 
WBC (10
3/μl) 6.57 ± 0.8 5.85 ± 0.4 5.70 ± 0.3 5.53 ± 0.4 4.0-12.0 
LYM (10
3/μl) 2.58 ± 0.5 2.28 ± 0.3 2.18 ± 0.2 1.98 ± 0.2 1.0-5.0 
MON (10
3/μl) 0.52 ± 0.08 0.37 ± 0.05* 0.42 ± 0.03 0.37 ± 0.05 0.1-1.0 
GRA (10
3/μl) 3.47 ± 0.3 3.22 ± 0.2 3.13 ± 0.2 3.20 ± 0.3 2.0-8.0 
LYM % 38.2 ± 3.1 38.3 ± 1.7 38.1 ± 1.3 35.9 ± 1.6 25.0-50.0 
MON % 7.60 ± 0.6 6.45 ± 0.5 7.00 ± 0.5 6.48 ± 0.4 2.0-10.0 
GRA % 54.3 ± 2.9 55.5 ± 2.0 54.9 ± 1.5 57.6 ± 1.3 50.0-80.0 
RBCc 
(10
6/μl) 
5.04 ± 0.4 5.02 ± 0.3 5.03 ± 0.4 4.80 ± 0.4 4.00-6.20 
HGB (g/dl) 13.2 ± 0.5 13.1 ± 0.6 12.9 ± 0.5 13.6 ± 0.3 11.0-18.0 
HCT % 40.0 ± 1.0 39.7 ± 1.2 39.6 ± 1.2 40.9 ± 1.1 35.0-55.0 
MCV (μm3) 81.4 ± 6.1 81.0 ± 6.2 80.7 ± 5.9 87.3 ± 6.0 80.0-100.0 
MCH (pg) 26.9 ± 2.2 26.8 ± 2.4 26.5 ± 2.3 29.2 ± 2.1 26.0-34.0 
MCHC (g/dl) 33.0 ± 0.6 32.9 ± 0.6 32.7 ± 0.6 33.3 ± 0.4 31.0-35.5 
RDW % 14.1 ± 0.5 14.0 ± 0.6 14.1 ± 0.7 13.7 ± 0.5 10.0-16.0 
PLT (10
3/μl) 263.7 ± 31.1 262.3 ± 18.5 256.2 ± 16.4 247.5 ± 20.1 150-400 
MPV (μm3) 8.24 ± 0.4 8.02 ± 0.4 7.94 ± 0.4 8.20 ± 0.5 7.0-11.0 
PCT % 0.212 ± 0.03 0.216 ± 0.02 0.210 ± 0.02 0.203 ± 0.02 0.200-0.500 
PDW % 15.1 ± 0.3 14.5 ± 0.6 15.0 ± 0.5 14.8 ± 0.5 10.0-18.0 
ESR (mm/h) 19.0 ± 7.5 19.0 ± 6.1 18.6 ± 7.4 20.8 ± 5.6 <20 
*Significant difference (p<0.05) from pre-intervention at the same condition. 
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Table 9. Indices of oxidative stress after PJ and CJ consumption in COPD patients. 
Index Pre BJ Post BJ Pre CJ Post CJ 
TAC (mmol DPPH/L) 1.15 ± 0.06 1.20 ± 0.05 1.17 ± 0.06 1.17 ± 0.05 
UA (mg/dl) 7.83 ± 0.6 7.93 ± 0.5 8.08 ± 0.4 7.95 ± 0.8 
Bilirubin (mg/dl) 0.66 ± 0.09 0.67 ± 0.10 0.65 ± 0.09 0.69 ± 0.09 
Catalase (U/g Hb) 344.0 ± 21.1 334.3 ± 18.0 322.1 ± 16.1 343.6 ± 17.6* 
*Significant difference (p<0.05) from pre-intervention at the same condition. 
 
Table 10. Indices of oxidative stress after PJ and CJ consumption in RA patients. 
Index Pre BJ Post BJ Pre CJ Post CJ 
TAC (mmol DPPH/L) 0.80 ± 0.03 0.82 ± 0.03 0.79 ± 0.03 0.80 ± 0.03 
UA (mg/dl) 5.51 ± 0.9 5.13 ± 0.8 5.79 ± 0.9 5.43 ± 0.8 
Bilirubin (mg/dl) 0.43 ± 0.04 0.45 ± 0.05 0.44 ± 0.05 0.45 ± 0.04 
Catalase (U/g Hb) 348.0 ± 23.3 346.2 ± 24.3 348.6 ± 23.6 346.9 ± 17.7 
 
Table 11. Indices of oxidative stress after PJ and CJ consumption in control group. 
Index Pre BJ Post BJ Pre CJ Post CJ 
TAC (mmol DPPH/L) 0.94 ± 0.04 0.98 ± 0.03 0.96 ± 0.04# 0.96 ± 0.04 
UA (mg/dl) 5.40 ± 0.7 5.32 ± 0.5 5.54 ± 0.5 5.67 ± 0.3 
Bilirubin (mg/dl) 0.90 ± 0.4 0.93 ± 0.3 0.96 ± 0.3 0.92 ± 0.3 
Catalase (U/g Hb) 328.3 ± 31.7 324.6 ± 25.1 330.9 ± 22.2 334.9 ± 27.9 
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Conclusions  
Based on the available data, beetroot appears to be a powerful dietary source of health promoting 
agents that holds potential as therapeutic treatment for several pathological disorders. The 
powerful antioxidant, anti-inflammatory and vascular-protective effects offered by beetroot and 
its constituents have been clearly demonstrated by several in vitro and in vivo human and animal 
studies; hence its increasing popularity as a nutritional approach to help manage cardiovascular 
disease and cancer. In the human studies to date, beetroot supplementation has been reported to 
reduce blood pressure, attenuate inflammation, avert oxidative stress, preserve endothelial 
function and restore cerebrovascular haemodynamics. Furthermore, although beyond the scope 
of this review, several studies have now established beetroot supplementation as an effective 
means of enhancing athletic performance [96,97]. 
The present work reveals that two weeks of BJ consumption may improve endothelial function in 
patients with RA and COPD. Since these patients are prone to CVD, this effect of BJ could elicit 
significant health benefits. Further research is needed to investigate the benefits of longer-term 
effects of BJ consumption on endothelial function and related cardiovascular health, as well as 
disease symptoms, and quality of life should be conducted. 
 
 
 
5. DISCUSSION 
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Dietary nitrate supplementation in COPD: An acute, double-blind, randomized, placebo-
controlled, crossover trial ☆ Conor P. Kerley a,b,*, Kathleen Cahill a, Kenneth Bolger a, Aisling 
McGowan a, Conor Burke a, John Faul a, Liam Cormican a a Respiratory and Sleep Diagnostics 
Department, Connolly Hospital, Blanchardstown, Dublin 15, Ireland b School of Medicine and 
Medical Sciences, University College Dublin, Belfield, Dublin 4, Ireland 
To our knowledge, this is the first trial of dietary nitrate in 
patientswithCOPD.Inthiscrossoverstudy,wedemonstratethatacute consumptionof 
BRJsignificantlyincreasedserumnitrate/nitrite,increased exercise capacity and 
decreased systemic arterial blood 
pressureinselectedpatientswithCOPD.Thesefindingssupportprevious findings of 
improved exercise capacity among healthy volunteers [10,22], athletes [11] and 
subjects with PVD [12] after nitrate consumption. 
Weobservedasignificantincreaseinserumnitrate >9fold(55– 508uM)andnitrite 
>4fold(139–612nM)3hafteringestionof BRJ compared with 3 h after PL (Fig.2). 
These values are similar to previous studies involving PVD subjects [12]. There 
was marked variation in the elevation of serum nitrate (375–1767%) and nitrite 
(−16% to +1662%) in response to BRJ. BRJ increased ISWT distance by 11% 
(−6% to +28%), while PL resulted in a decrease of 7.6% (−33% to 0%) (Fig. 3). 
ISWT responses varied (−10 to +80 m). Our data suggest that dietary nitrate 
supplementation appears to abrogate 
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exercise related fatigue in some patients with COPD, but the effect is 
unpredictable. Wecannotfullyexplainthevariationinresponseofserumnitrate/ nitrite 
responses and exercise capacity to BRJ and PL. Advanced age [23], specific 
medications [24], altered oral bacteria [25] and stomach acidity [24] may partially 
account for the variation in serum nitrite in response to dietary nitrate provision. It 
is noteworthy that there was a strong correlation between the elevations in serum 
nitrate and serum nitrite (r = 0.83, p = 0.0015) (data not shown) suggesting that the 
elevation in serum nitrite may depend on the elevation in serum nitrate. Potential 
contributors to the varied exercise response include: differences in habitual 
physical activities, COPD severity and nitrate/nitrite conversion. Some studies of 
nitrate supplementation and exercise performance have shown varied beneficial 
changes [10–12,22,26,27] but othersshownoeffect [28].Manyof 
thesestudies,similartoourobservations,reportedinter-
individualvariabilitybothinbiochemical and physiological responses to dietary 
nitrate. A recent report has 
suggestedthatageneticinfluenceispossible[29].Wedidnotassess genotype here. It is 
difficult to compare our results with other studies, as the protocols differ in terms of 
nitrate dosing, exercise assessment and population studied. Our trial involved 
COPD subjects performing a progressive and maximal exercise test of short 
duration (0.33– 7.6min). Previous reports of nitrate provision before short, intense 
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exercisehavenotedimprovements [11].Inaddition,nitratesupplementation has 
previously been demonstrated to improve exercise tolerance in hypoxic conditions. 
In one trial, 9.3mmol nitrate increased time to exhaustion by 15% compared with 
placebo during a 5–10m constant-load maximal knee-extension test [22]. Similarly, 
0.07mmol nitrate/kg body wt resulted in 36% greater time to exhaustion during a 
maximal incremental cycle test [27]. Finally, our results parallel those from a trial 
of inorganic nitrate supplementation in a PVD population – a disease characterized 
by peripheralischemiauponexertion.12.1mmoldietarynitrateacutely 
increasedexercisetoleranceby17%[12].Alikelyexplanationisthat 
thesetrialshavebeenperformedinstatesassociatedwithlowtissue 
oxygentension,suchashypoxia,ischemia,and,acidosis.Itisknown that during these 
conditions the nitrate–nitrite–NO pathway is upregulated [6]. In contrast to 
previous reports [10,12], there was no correlation between absolute change in 
exercise performance/MAP and percent change in serum nitrite (Fig.3a and b). A 
potential explanation for this finding is that we included heterogeneous COPD 
subjects, differing by COPD severity, age, BMI and smoking history. 
Additionally,themajorityofparticipantshadmultipleco-morbidities and hence 
complex medication regimens. 
Nineofelevensubjects(82%)hadincreasedexercisecapacityafter 
BRJcomparedwithPL.Onesubjectwalkedidenticaldistancesbefore 
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andafterbothBRJandPL(100m).Thissubjecthadthemostsevere (GOLD stage IV; 
FEV1% = 15) and was the only current-smoker. Smoking may interfere with 
nitrate/nitrite metabolism [30]. The secondnon-
responderwalked10mlessontheISWTafterBRJ(150 to 140m) compared with PL 
(140m before and after PL), and was the only subject who had a decrease in serum 
nitrite following BRJ. This subject was taking a proton pump inhibitor 
(Lansoprazole). It is known that the acidic conditions of the stomach upregulate the 
reductionof nitritetoNO [24].Itispossiblethatincreasedstomach pH may account for 
the decreased serum nitrite and lack of exercise benefit due to nitrate 
supplementation in this subject. We also observed significant decreases in resting 
systolic BP (−12.8 mmHg), diastolic BP (−3.2mmHg), and MAP (−6.2mmHg) 
(Table3). This is noteworthy as hypertension is a frequently 
occurringcomorbidityinCOPD [31].Indeed,6(55%)of ourstudysample were 
established on anti-hypertensive therapy. This observation is consistent with some 
previous reports of BP reductions following 
dietary nitrate supplementation [10,12,32]. There was no significant difference 
between the two beverages regarding %SpO2, HR or dyspnoea either before- or 
after-ISWT (Table3). Considering that 
mostsubjectswalkedfurtherwithBRJ,changesin%SpO2,HRordyspnoea would have 
been unlikely. Even though exercise testing is frequently used in the clinical 
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evaluation of patients with COPD and to evaluate the functional impactof 
atreatment[33]quantifyingimprovementinexercisetolerance is difficult. Hence, there 
is no consensus regarding which exercise testing protocol should be used to assess 
COPD symptomsandtreatmentimpact.ISWTperformancemorestronglyreflects 
theabilitytoundertakeeverydayphysicalactivitiesthanlaboratorybasedtesting[34].Alt
houghISWTisavalidatedmeasureof exercise 
capacityinCOPD[17,35]andhasexcellenttest–retestreliability[35], its use does not 
elucidate the mechanism(s) involved. 
Potential mechanisms 
Several mechanisms may have contributed to our observed results and suggested mechanisms by 
which dietary nitrate improved exercise capacity have recently been reviewed [36] and include 
reduced O2 cost of exercise [10], increased mitochondrial eficiency [36], as well as increased 
oxygenation status [12,27] and blood volume in active skeletal muscle [10,12]. Further 
mechanisms may include an improvement in dynamic hyperinflation and a pulmonary 
vasodilatory action, leading to abrogation of ventilation mismatch during exercise. However in 
this pilot study, we did not explore mechanisms. 
Limitations 
Our study has several important limitations. We did not use a true placebo but rather 
manufactured a similar appearing and tasting no-nitrate, placebo juice. 
However,aresearchernotinvolvedintheassessmentsblindedthebeveragesandtherefore
study subjects and assessors were blinded throughout. Nevertheless, BRJ contains 
multiple, non-nitrate components that may influence 
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exerciseperformancee.g.betaine,potassium,carbohydrateenergy(as 
sugar),antioxidants,andpolyphenols.Wefeelitisunlikelythatany of these food 
components account for the acute improvement in exercise capacity we observed. 
For example, the BRJ contained 146kcal from carbohydrates compared with 
26kcal in the PL. It is unlikely that the energy content of the BRJ accounts for our 
observations. Vermeeren et al. (2001) [37] demonstrated no difference 
inexercisecapacity(submaximalcycleenduranceexercisetest)followingacuteconsum
ptionof a250kcalcarbohydratedrinkamong COPD subjects. Multiple investigations 
have noted superiority of nitrate rich BRJ compared with a recently developed, 
nitrate 
Furthermore, previous trials utilizing BRJ vs.anon-BRJ,nitrate-
freejuicehaveshownthatBRJresultedinbeneficial exercise/BP response compared 
with PL [12,26]. Therefore, we feel it is likely that the inorganic nitrate was 
responsible for the observed effects. While a limitation of this study is the 
heterogeneous nature of thesamplestudied,thisisrepresentativeof 
theCOPDspectrumobservedclinically [31].Whetherourresultscanbeappliedtoalarger 
group of COPD subjects in the chronic setting requires further research. Another 
limitation is the absence of the ISWT practice walk as 
recommended[16].Theprotocolwasidenticalonbothvisitsexcept for the beverages. 
Seven (63%) of our subjects were randomly 
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assignedtoBRJfollowedbyPL.Meanbaseline(i.e.pre-beverage)ISWT scores were 
found to be similar between weeks 1 and 2 (197.6 vs. 195 m) (Fig. 3). Therefore, it 
is unlikely the increased exercise capacity we observed with BRJ can be attributed 
to a learning effect. Although NO may be important in COPD, therapy with 
inhaled NO has yielded disappointing results in COPD and can worsen ventilation 
perfusion matching [13]. Indeed, inhaled NO is 
contraindicatedinCOPDasperthe2013GlobalStrategyfortheDiagnosis, Management 
and Prevention of COPD (2014) [38] guidelines. No recommendation exists about 
the benefits or risks of supplementaldietarynitrate.However,directconsumptionof 
nitrite(typically in the form of processed meat) has been associated with COPD 
incidence and severity [39]. Nitrite formed endogenously from dietary nitrate 
appears beneficial by forming NO endogenously, whereas directly consumed 
nitrite has been associated with detrimental effects, potentially by forming 
carcinogenic nitrosamines. 
4.3. Clinical relevance 
The same group who developed the ISWT recently recommended the minimum 
clinically important improvement for the ISWT to 47.5m ([40]). According to this 
criteria, 3 of our 12 subjects (25%) improved to a clinically significant degree (+ 
50, 70, 80m respectively). Ever decreasing exercise tolerance is central to the 
progression of the downward spiral of COPD. Augmenting chronic dietary nitrate 
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intake through nutritional strategies may represent a possible opportunity to impact 
on exercise tolerance in COPD; however we did not assess chronic effects in this 
study. 
5. Conclusions 
Acutesupplementationofdietarynitrateincreasedserumnitrate/ 
nitritelevels.Thiscorrespondedtoameanincreaseof11%indistance walked on ISWT 
and a 5.4% decrease in MAP. However, our preliminary trial has important 
limitations, namely the inclusion of a small, heterogeneous sample, short trial 
period (3h) and the lack of a true placebo. Since COPD is often associated with 
decreased exercise capacity, nitrate-rich vegetables may represent an inexpensive, 
acceptable, novel, adjunct therapeutic option. Our 
preliminaryacuteresultsrequireconfirmationwithalargersample, a true placebo and a 
longer intervention period. 
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6. CONCLUSIONS AND DIRECTIONS FOR FUTURE RESEARCH 
Nutritional status is an important determinant of outcome of COPD and RA and may be assessed 
by longitudinal measurement of body weight and body composition. 
The prevalence of vitamin D nutrient deficiency is high in COPD and could be incorporated into 
nutritional risk screening. 
The nutritional risk profiles associated with different metabolic phenotypes of COPD patients 
could be useful in patient counselling. 
Nutritional intervention is likely to be effective in undernourished patients (based on the 
Cochrane review [66]) and is probably most effective if combined with an exercise programme. 
Providing evidence of the cost-effectiveness of nutritional intervention is required to support 
reimbursement of, and thus increase access to, nutritional intervention. 
Overall, the evidence indicates that a well-balanced diet with sufficient intake of fresh fruits and 
vegetables is beneficial to COPD patients, not only for its potential benefits on the lung but also 
for its proven benefits on metabolic and cardiovascular risk. 
Future research priorities 
Nutritional assessment 
Validate the criteria for risk stratification phenotypes of COPD as set out in figure 1  
Investigate whether these phenotypes are characterised by specific mechanisms/pathophysiology 
Standardise protocols for lifestyle determinants (diet, smoking and physical activity level) and 
for metabolic phenotyping to facilitate betweencentre comparisons and multicentre studies 
Pathophysiology of abnormal body composition 
Explore the role of systemic inflammation and of inflammatory genotypes on body composition 
changes. 
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Explore the role of adipose tissue macrophages in the systemic inflammatory response and 
related extra pulmonary pathology, consider sex differences in adipose tissue metabolism and 
inflammation, and investigate effects of COPD exacerbations on adipose tissue inflammation and 
metabolism. 
Investigate the aetiology of muscle wasting on a cellular basis by analysing the regulatory and 
effector pathways of muscle protein and myonuclear turnover in muscle biopsies of in well-deep 
phenotyped COPD patients and by longitudinal data collection. 
Investigate the added value of pharmacological modulation of regulatory pathways of 
proteolysis, including NF-kB, FOXO, MAPK, or their triggers oxidative stress and inflammation 
on the outcome of anabolic nutritional and multimodal interventions. 
Analyse the impaired response to anabolic stimuli after acute nutritional, pharmacological or 
exercise challenges in analogy to the glucose tolerance test. 
Investigate the putative influence of abnormal microbiota shifts in the lung or intestine on 
abnormal metabolic phenotypes. 
Determine whether targeting exacerbations with intensive nutritional therapy (perhaps combined 
with exercise and anabolic drugs) would improve outcome. 
Determine the effectiveness and safety of weight reduction programmes in obese patients with 
COPD and RA. 
Outcome analysis 
It is likely that the benefits of supplementation will be maximised if combined with exercise, 
although based on the current literature, the effects of nutrition and exercise cannot clearly be 
distinguished, which is a subject for future research. 
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Cost-effectiveness 
Assess the added value of oral nutritional supplements and long-term nutritional counselling in 
terms of costs and effects in different phenotypes in RCTs 
Use of real-life data from continuous patient registries in weight-losing patients for cost-
effectiveness analysis of dietary counselling and nutritional supplements 
Use longitudinal real-life data from patient registries to study the association between change in 
body composition and disease progression risk, functional impairment, hospitalisations and 
mortality; this information can be used to perform a model-based analysis of long-term cost-
effectiveness of nutritional interventions 
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APPENDIX Ι 
 
Έγκριση επιτροπής βιοηθικής 
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APPENDIX ΙΙ 
 
Τ.Ε.Φ.Α.Α., ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΙΑΣ 
 
ΣΤΟΙΧΕΙΑ ΣΥΜΜΕΤΕΧΟΝΤΟΣ 
ΟΝΟΜΑΤΕΠΩΝΥΜΟ:  
ΗΜΕΡΟΜΗΝΙΑ ΓΕΝΝΗΣΗΣ:  
ΗΜΕΡΟΜΗΝΙΑ:  
ΚΩΔΙΚΟΣ ΣΥΜΜΕΤΕΧΟΝΤΑ:  
 
ΑΝΘΡΩΠΟΜΕΤΡΙΚΑ ΧΑΡΑΚΤΗΡΙΣΤΙΚΑ 
 
Μέτρηση 1
η 
 2
η
  3
η
  4
η
  
Βάρος (kg) 
 
    
Ύψος από όρθια θέση (cm) 
 
    
Ποσοστό σωματικού λίπους 
 
    
Ποσοστό ενυδάτωσης 
 
    
Λόγος περιμέτρου μέσης /γοφών 
(WHR) 
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ΚΥΚΛΟΦΟΡΙΚΟ – ΚΑΡΔΙΑ 
 
Μέτρηση 1
η
 2
η
 3
η
 4
η
 
Αρτηριακή πίεση ηρεμίας 
 
    
Καρδιακή συχνότητα 
ηρεμίας 
 
    
 
 
Παρατηρήσεις 
 
 
 
Μέτρηση 
1
η
 2
η
 3
η
 4
η
 
6 min walk test     
Σπιρομέτρηση     
 
 
Ο ΥΠΕΥΘΥΝΟΣ ΤΟΥ ΕΡΓΑΣΤΗΡΙΟΥ 
(Υπογραφή) 
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APPENDIX ΙΙΙ 
 
Ερωτηματολόγιο υγείας 
 
Όνομα.................................................................................................................................... 
Ημερομηνία.......................................................................................................................... 
 
Παρακαλώ συμπληρώστε 
 
1. Έχετε κάποιο πρόβλημα υγείας για το οποίο  
Α) είστε υπό φαρμακευτική αγωγή ναι [  ] όχι [  ] 
Β) είστε υπό ιατρική παρακολούθηση ναι [  ] όχι [  ] 
 
2. Τα τελευταία 2 χρόνια, εξαιτίας κάποιας ασθένειας 
Α) επισκεφτήκατε το γιατρό σας ναι [  ] όχι [  ] 
Β) επισκεφτήκατε εξωτερικά ιατρεία  ναι [  ] όχι [  ] 
Γ) μείνατε στο νοσοκομείο ναι [  ] όχι [  ] 
 
3. Είχατε ποτέ κάποια από τις παρακάτω καταστάσεις; 
Α) Επιληψία ναι [  ] όχι [  ] 
Β) Έκζεμα ναι [  ] όχι [  ] 
Γ) Διαβήτης ναι [  ] όχι [  ] 
Δ) Άσθμα ναι [  ] όχι [  ] 
Ε) Καρδιαγγειακά νοσήματα ναι [  ] όχι [  ] 
Ζ) Πεπτικά προβλήματα ναι [  ] όχι [  ] 
Η) Προβλήματα γυναικολογικά  ναι [  ] όχι [  ] 
Θ) Προβλήματα οστών και αρθρώσεων ναι [  ] όχι [  ] 
Ι) Προβλήματα ισορροπίας και συναρμογής ναι [  ] όχι [  ] 
Κ) Προβλήματα όρασης/ ακοής ναι [  ] όχι [  ] 
Λ) Προβλήματα θυρεοειδούς ναι [  ] όχι [  ] 
Μ) Ορμονικά προβλήματα ναι [  ] όχι [  ] 
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Ν) Προβλήματα ήπατος και νεφρών ναι [  ] όχι [  ] 
Ξ) Μούδιασμα άκρων ναι [  ] όχι [  ] 
Ο) Άλλα προβλήματα ναι [  ] όχι [  ] 
 
4. Αν είστε γυναίκα 
Α) σχεδιάζετε να μείνετε έγκυος ναι [  ] όχι [  ] 
Β) είστε η νομίζετε ότι είστε έγκυος ναι [  ] όχι [  ] 
Γ) παίρνετε χάπια αντισύλληψης ή ορμόνες ναι [  ] όχι [  ] 
Δ) είστε στην εμμηνόπαυση ναι [  ] όχι [  ] 
 
5. Κάποιος από τους συγγενείς πρώτου βαθμού είχε  
Α) Καρδιαγγειακά προβλήματα ναι [  ] όχι [  ] 
Β) Διαβήτη ναι [  ] όχι [  ] 
Γ) Εγκεφαλικό ναι [  ] όχι [  ] 
Δ) Κάποια άλλη ασθένεια ναι [  ] όχι [  ] 
 
6. Καπνίζετε αυτή την περίοδο ναι [  ]  όχι [  ] 
Έχετε καπνίσει ποτέ ναι [  ]  όχι [  ] 
Αν ναι, για πόσο καιρό και πότε το κόψατε............................................................... 
Πόσες μονάδες αλκοόλ πίνετε σε μια εβδομάδα....................................................... 
 
7. Γυμνάζεστε ναι [  ] όχι [  ] 
 
Πόσες φορές την εβδομάδα....................................................................................... 
 
Αναφέρετε το είδος γυμναστικής............................................................................... 
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Αν απαντήσατε ναι σε κάποια από τις ερωτήσεις, παρακαλώ περιγράψτε εν συντομία 
............................................................................................................................................................
............................................................................................................................................................
............................................................................................................................................................
............................................................................................................................................................
............................................................................................................................................................
............................................................................................................................................................
.................................................................................................................................................... ........
............................................................ 
 
 
Δηλώνω ότι είμαι σωματικά υγιής και δεν πάσχω από κάποια πάθηση, βλάβη, 
ασθένεια ή αναπηρία που θα μπορούσε να εμποδίσει τη συμμετοχή μου στην 
πειραματική διαδικασία. 
Αναγνωρίζω ότι έχω εξετασθεί και ο γιατρός μου έχει δώσει την άδεια να 
συμμετάσχω, ή έχω αποφασίσει να συμμετάσχω στην πειραματική διαδικασία 
χωρίς την έγκριση του γιατρού μου. Αναλαμβάνω κάθε ευθύνη για την 
συμμετοχή μου.  
 
 
Ημ/νία      
 
    
Υπογραφή ερευνητή                                                                   Υπογραφή συμμετέχοντα 
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APPENDIX ΙV 
 
ΔΙΕΘΝΕΣ ΕΡΩΤΗΜΑΤΟΛΟΓΙΟ ΦΥΣΙΚΗΣ ΔΡΑΣΤΗΡΙΟΤΗΤΑΣ (IPAQ) 
 
Όνομα/ Κωδικός: 
Ημερομηνία: 
 
Ενδιαφερόμαστε να μάθουμε για τις σωματικές δραστηριότητες που κάνουν οι άνθρωποι σαν 
κομμάτι της καθημερινής τους ζωής. Οι ερωτήσεις αναφέρονται σε δραστηριότητες που κάνατε 
τις τελευταίες 7 ημέρες. Παρακαλούμε απαντήστε σε όλες τις ερωτήσεις ακόμα και αν δεν 
θεωρείτε τον εαυτό σας δραστήριο άτομο. Παρακαλούμε σκεφτείτε τις δραστηριότητες που 
κάνετε στην εργασίας σας, σαν μέρος της δουλειάς που κάνετε στο σπίτι και στην αυλή, για να 
μετακινηθείτε από ένα μέρος σε άλλο και στον ελεύθερο χρόνο σας για αναψυχή, εξάσκηση ή 
για σπορ. 
 
Σκεφτείτε όλες τις έντονες δραστηριότητες κάνατε τις τελευταίες 7 ημέρες. Οι έντονες 
σωματικές δραστηριότητες χρειάζονται προσπάθεια  και μπορεί να σας κάνουν να αναπνέετε πιο 
δύσκολα από το κανονικό. Σκεφτείτε μόνο εκείνες τις σωματικές δραστηριότητες που κάνατε 
για τουλάχιστον 10 λεπτά συνεχόμενα. 
 
1. Κατά ην διάρκεια των τελευταίων 7 ημερών, πόσες μέρες κάνατε έντονες σωματικές 
δραστηριότητες όπως το να σηκώσετε βαριά αντικείμενα, σκάψιμο, aerobics ή γρήγορο 
ποδήλατο; 
      ____ Ημέρες ανά εβδομάδα.  
     Καμιά έντονη σωματική δραστηριότητα => περάστε στην ερώτηση 3. 
 
2. Πόσο χρόνο καταναλώσατε σε έντονες σωματικές δραστηριότητες την κάθε μία από αυτές τις 
ημέρες; 
      ____ Ώρες ανά ημέρα 
      ____ Λεπτά ανά ημέρα  
      Δεν ξέρω/ δεν είμαι σίγουρος 
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Σκεφτείτε όλες τις δραστηριότητες που χρειάζονται μέτρια σωματική προσπάθεια και τις οποίες 
κάνατε τις τελευταίες 7 ημέρες. Οι μέτριες σε ένταση δραστηριότητες μπορεί να σας κάνουν να 
αναπνέετε πιο λίγο πιο δύσκολα από το κανονικό. Σκεφτείτε μόνο εκείνες τις σωματικές 
δραστηριότητες για τις οποίες διαθέσατε τουλάχιστον 10 λεπτά συνεχόμενα. 
 
3. Κατά την διάρκεια των τελευταίων 7 ημερών, πόσες μέρες κάνατε μέτριες σωματικές 
δραστηριότητες όπως τη μεταφορά ελαφριών φορτίων, ποδήλατο σε κανονικό ρυθμό, ή τένις. 
Μην συμπεριλάβετε το περπάτημα. 
      ____ Ημέρες ανά εβδομάδα.  
    Καμιά μέτριας έντασης σωματική δραστηριότητα => περάστε στην ερώτηση 5 
 
4. Πόσο χρόνο καταναλώσατε συνήθως σε μέτριες σωματικές δραστηριότητες την κάθε ημέρα; 
      ____ Ώρες ανά ημέρα 
      ____ Λεπτά ανά ημέρα  
     Δεν ξέρω/ δεν είμαι σίγουρος 
 
Σκεφτείτε το χρόνο που διαθέσατε στο περπάτημα τις τελευταίες 7 ημέρες. Αυτό περιλαμβάνει 
και το περπάτημα στο σπίτι και στη δουλειά, την μετακίνηση από το ένα μέρος στο άλλο και 
οτιδήποτε περπάτημα κάνετε απλά στον ελεύθερο σας χρόνο για άθληση, εξάσκηση η αναψυχή. 
 
5. Κατά τις τελευταίες 7 ημέρες πόσες μέρες περπατήσατε για τουλάχιστον 10 λεπτά 
συνεχόμενα; 
      ____ Ημέρες ανά εβδομάδα.  
 Καθόλου περπάτημα = περάστε στην ερώτηση 7 
 
6. Πόσο χρόνο συνήθως περάσατε περπατώντας  μία από αυτές τις ημέρες; 
      ____ Ώρες ανά ημέρα 
      ____ Λεπτά ανά ημέρα  
      Δεν ξέρω/ δεν είμαι σίγουρος 
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Σκεφτείτε το χρόνο που περάσετε καθισμένοι κατά τις εργάσιμες ημέρες στο διάστημα των 
τελευταίων 7 ημερών. Συμπεριλάβετε τον χρόνο στη δουλειά, στο σπίτι, στη διάρκεια 
μαθημάτων ή της ξεκούρασης. Αυτό μπορεί να περιλαμβάνει τον χρόνο που περάσατε 
καθισμένοι σε ένα θρανίο, επισκεπτόμενοι φίλους, διαβάζοντας ή τον χρόνο που περάσατε 
καθισμένοι ή ξαπλωμένοι βλέποντας τηλεόραση. 
 
7. Κατά τη διάρκεια των τελευταίων 7 ημερών, πόση ώρα περάσατε καθισμένοι σε μία από τις 
εργάσιμες ημέρες; 
      ____ Ώρες ανά ημέρα   
      ____ Λεπτά ανά ημέρα   
Δεν ξέρω/ δεν είμαι σίγουρος 
 
Αυτό είναι το τέλος του ερωτηματολογίου, ευχαριστούμε για την συμμετοχή σας 
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APPENDIX V 
 
ΔΙΑΤΡΟΦΙΚΗ ΑΝΑΚΛΙΣΗ 24ΩΡΟΥ (24h recall) 
 
Όνομα/ Κωδικός: 
Ημερ/νία: 
 
ΒΗΜΑ 1: Λίστα τροφών που καταναλώθηκαν εχθές/ μια τυπική ημέρα 
 
1. ΠΡΩΙΝΟ 
 
 
2. ΠΡΟΓΕΥΜΑ 
 
 
3. ΜΕΣΗΜΕΡΙ 
 
 
4. ΑΠΟΓΕΥΜΑ 
 
 
5. ΒΡΑΔΥ 
 
 
6. ΑΛΛΟ 
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ΒΗΜΑ 2: Αναλυτική περιγραφή τροφίμων 
 
Ερωτήσεις περιγραφής 
- Θυμάσαι κάτι άλλο που κατανάλωσες με αυτό το φαγητό? 
- Τι άλλο έφαγες σε αυτό το γεύμα? 
- Σε αυτό έβαλες κάτι από πάνω? 
Ερωτήσεις τύπου τροφίμου 
- Τύπος φαγητού, μορφή, μέθοδος παρασκευής, εταιρεία παρασκευής, ποσότητα και μέρη, 
υλικά, επιπρόσθετα 
Ερωτήσεις ωραρίου 
- Ποιό ήταν το πρώτο πράγμα που έφαγες όταν ξύπνησες το πρωί? 
- Έφαγες κάτι μετά τα μεσάνυχτα? 
- Έφαγες ή ήπιες κάτι όταν βγήκες έξω? 
Ερωτήσεις δραστηριότητας 
- Καθώς δούλευες (εντός ή εκτός σπιτιού) έκανες κάποιο διάλειμμα να φας ή να πιείς 
κάτι? 
- Είδες τηλεόραση εχθές? Καθώς έβλεπες τηλεόραση έτρωγες κάτι παράλληλα? 
- Σταμάτησες στο δρόμο από το σπίτι στη δουλειά να πάρεις κάποιο φαγητό ή ποτό? 
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Ομάδες τροφίμων/ Προτιμήσεις 
Δημητριακά (ΝΑΙ/ ΟΧΙ, περιγραφή) 
ψωμί  
ρύζι  
δημητριακά  
πατάτες  
ζυμαρικά  
Φρούτα  
εσπεριδοειδή  
χυμοί  
άλλα φρούτα  
ξερά φρούτα  
Λαχανικά  
Κρέας  
ψάρι  
θαλασσινά  
αυγά  
όσπρια  
ξηροί καρποί  
Γαλακτοκομικά 
προΐόντα (γάλα, 
γιαούρτι, τυρί κτλ) 
 
Λίπη, Έλαια, Γλυκά 
(ελιές, ελαιόλαδο, 
σπορέλαιο, 
μαγιονέζα, 
μαργαρίνη, 
βούτυρο, σάλτσες, 
σως, ζάχαρη) 
 
Νερό  
Αλάτι  
Αλκοόλ  
Αναψυκτικά  
Άλλο, σούπες, 
snacks, τσάι, καφές 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:03:26 EEST - 137.108.70.13
Σ ε λ ί δ α  | 130 
 
130 
 
APPENDIX VI 
 
COPD - Kλίμακα δύσπνοιας ΜRC 
 
Ημερομηνία:  
Κωδικός: 
 
Με την παρακάτω κλίμακα, ο εξεταζόμενος βαθμολογείται από 0-4, ανάλογα με την ικανότητά 
του στην κίνηση. Με την κλίμακα MRC δεν αποτιμάται η ένταση της δύσπνοιας, αυτής 
καθαυτής, όπως με τις αναλογικές ή κατηγορικές διαβαθμίσεις, αλλά μόνο η σχέση της με 
τροποποιημένη δραστηριότητα (Προσαρμογή από Fletcher et al., 1959). 
 
0 Απουσία δύσπνοιας εκτός από την περίπτωση έντονης σωματικής άσκησης 
1 Εμφάνιση δύσπνοιας όταν βιάζεται στο ίσιωμα ή όταν ανεβαίνει σε μικρή ανηφόρα 
2 
Βαδίζει βραδύτερα από ανθρώπους της ίδιας ηλικίας στο ίσιωμα ή σταματά όταν βαδίζει 
με το δικό του βήμα στο ίσιωμα 
3 Σταματά για να ανασάνει όταν βαδίζει 100 μ. ή μετά από λίγο στο ίσιωμα    
4 
Πολύ μεγάλη δύσπνοια για να μπορέσει να βγει από το σπίτι  ή όταν ντύνεται ή 
ξεντύνεται 
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APPENDIX VIΙ 
 
RA - DAS28 
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APPENDIX VIIΙ 
 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:03:26 EEST - 137.108.70.13
Σ ε λ ί δ α  | 133 
 
133 
 
APPENDIX IX 
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